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ABSTRACT 
Medicines are an important intervention for protecting public health. While medicines 
have brand and generic type products, those used for treating non-communicable 
diseases are used by patients for life. 
The pharmaceutical market is not a competitive market with asymmetric flow 
of information. Equal access to both types of medicines is part of equal access to 
health care in different socioeconomic areas. Patients with non-communicable 
diseases should own their choice of whether brand or generic medicines for their 
treatment not the market supply that dictates their consumption. 
In this thesis, we used data for availability of 39 medicines treating non-
communicable diseases selected based on some inclusion criteria.  
Our hypothesis assumed social equity that presumes equal access to both medicine 
types in varying rural and urban areas where population having chronic conditions 
have to acquire their treatments for life. Data was modeled and logistic regression was 
used. Results were produced using statistical software; both SPSS and R. 
Primary findings show that rural and urban areas have different pattern of 
market supply for both brand and generic medicine types. In the same settings of a 
socioeconomic area, the probability of supply of brand rather than generic medicines 
increases by the increase in price. 
Social health insurance coupled by pharmaceutical Track and Trace system and 
combined pricing mechanisms should be in place to insure equilibrium between 
market supply and equal access to medicines. Patients with non-communicable 
diseases in different urban and rural areas in Egypt should be left to consume their 
medicine type at their choice. Guidelines for promotion of prescription medicines, 
guidelines for prescribing practices should be in place to improve the market 
equilibrium. 
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Introduction 
 
 
Global Market 
Medicines are important intervention device to preserve and improve 
people's health. It is a major input for improving health outcomes when it is provided 
in the right place and in right time. Regardless of the patients' socioeconomic 
classification, health is always their naturally granted wealth sought to be kept in a 
well-being status. 
The global pharmaceuticals market is worth US$300 billion a year, a figure expected 
to rise to US$400 billion within three years (WHO, 2016). The 10 largest drugs 
companies control over one-third of the global market, several with sales of more than 
US$10 billion a year with a profit margins of about 30 percent.  
Medicines account for 20–60 percent of health spending in Low- and Middle-Income 
Countries (LMIC) compared to 18% in countries of the Organization for Economic 
Co-operation and Development (OECD). In developing countries, up to 90 percent of 
the population purchases medicines through out-of-pocket payments, making 
medicines the largest household expenditure item after food. As a result, medicines, 
particularly those with higher costs, may be unaffordable for large sections of the 
global population and are a major burden on government budgets (WHO, 2016).  
Increasing expenditures on drugs put pressure on policy makers to control drug costs 
and ensure that these resources are well spent. Pharmaceuticals make an important 
contribution to people’s health. However, drugs are frequently not used appropriately 
(OECD, 2002). Rational use of medicines and proper prices will decrease these 
expenditure and lower that pressure on policy makers. 
Expenditure on pharmaceuticals in US was $235 billion in 2005, while for OECD 
countries it was $569 billion (OECD, 2008). The pharmaceutical expenditure share of 
health care expenditure varies from 19 % in high income countries to 30% in low 
income countries (WHO, 2011). Whether prices of medicines are determinant of total 
expenditure on health or not, equal access to medicine is a right for all people. 
Initiatives to stimulate availability and access through manufacturing innovations, 
Brand and Generic Medicines Supply to Socioeconomic Areas of Egypt  
 
2 
 
procurement mechanisms, or supply chain improvements require management of 
pricing to have sustainable impact. 
Pharmaceutical pricing regulations can be found in most of the European and Middle 
Eastern countries (Wertheimer et al, 1992). Pricing policies set as part of government 
intervention is necessary to achieve public health objectives and to mitigate any 
market (Quick, 1997). Some countries, such as France and Italy, regulate drug prices 
directly through price control; others, such as Australia, Germany, Japan, India, Peru, 
Bolivia, Guatemala use other measures to directly or indirectly control prices 
(Danzon, 2000).  
 
Egypt Context 
The pharmaceutical market in Egypt is one of the largest in the Middle East and 
Africa (Al-Ali, 2002). It is worth around $4.4billion as foreseen by Business Monitor 
International Report (BMI, 2015Q2). Pharmaceutical products have to be registered 
before any Marketing Authorization (MA) granted for the product following Law 
127/1955. Although there are over 14,000 medicines registered in Ministry of Health, 
only 12,500 medicines are marketed and available in the market (MOH, 2015), due to 
challenges of production costs against the obligatory pricing and some of those are 
still in the registration pipeline, while others face challenges importing the active 
pharmaceutical ingredients and other chemicals used in production due to shortages of 
foreign currency cash flow. The pharmaceutical industry is composed of both local 
and multinational companies in addition to scientific offices, and toll-manufacturing1 
companies.  
Medicines in Egypt are government-regulated and its price is controlled by law and 
ministerial decrees. Pricing is an essential step in the registration process of any 
pharmaceutical product. The pricing takes place through a pricing committee 
composed of experts from different disciplines.  
 
Generic pharmaceutical products have to undergo a bioequivalence 2test with the 
brand medicine prior to its final MA is granted. This test ensures that both generic and 
                                                             
1 Firms that do not have its own manufacturing site. Instead, contracts with the existing factories to 
are approved to manufacture their products. 
2 Test used to assess two pharmaceutical products are bioequivalent; i.e.: pharmaceutically equivalent 
and their bio-availabilities after administration are similar to such a degree that their effects, with 
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brand medicines have the same biological characteristics and therapeutic potency as 
the brand medicine when administered to patients. All generic and brand medicines 
are analyzed for conformity against quality tests and registration dossier before its 
release to the market. 
Patients have to pay out-of-pocket (OOP) for their medicines. The public health 
insurance covers only 58% of the population. Public hospitals adhere to a list of 
standard medicines that are publicly tendered and procured centrally. Patients have to 
purchase their medicines if not on the list of the public tender medicines. Private 
pharmacies are licensed by the MOH3 and considered as the main legal outlet to sell 
medicines (i.e.: medicines are not sold in groceries or any commercial store other than 
the pharmacy4) 
Although Egypt’s pharmaceutical expenditure per capita is one of the lowest in the 
MENA region, it is still the largest market of pharmaceuticals among African and 
Arab countries (AmCham, 2015). Its infrastructure of pharmaceutical manufacturers, 
distributors, warehouses, and pharmacy outlets exceeds that of any other market in the 
region. However, the public health expenditure is still low compared to other 
countries. 
Securing access to affordable medicines in Egypt requires considering the interests of 
all stakeholders involved in a pricing policy, namely patients and industry. 
Affordability comes at the forefront as a major determinant of access, given that 
patients are more likely to pay for their treatment OOP (Wanis, 2014). There is recent 
research done on medicine affordability in Egypt and its effect on access to medicines 
(HAI, 2014).  
The affordability survey findings showed that when using generics, most standard 
treatments required less than 1 day wages upon purchasing 30 days treatment for 
NCDs. For treatment for hypertension, diabetes and hypercholesterolemia, then the 
patient would spend 2 to 7.8 days of wages every month to purchase medicines, 
depending upon the choice of medicine and product type (HAI, 2014). Some of the 
affordability findings and figures are shown in Annex. 
                                                                                                                                                                              
respect to both efficacy and safety, can be expected to be essentially the same. Pharmaceutical 
equivalence implies the same amount of the same active substance(s), in the same dosage form, for 
the same route of administration and meeting the same or comparable standards (BirkeƩ, 2003). 
3 Mandated by Law 127/1955 -arƟcle(11) 
4 Mandated by Law 127/1955 -arƟcles (32,37)  
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The Egyptian pharmaceutical market is expected to continue to grow. Reasons for 
growth include the increasing prevalence of non-communicable diseases, which 
require long-term treatments, consequently improving access is necessary step 
forward (AmCham, 2015).  
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Chapter 1: Background 
 
Egypt Health Profile Egyptian Market Structure 
The Arab Republic of Egypt is a lower-middle income country with a population 
size of 90.5 million (CAPMAS, 2016). The gross domestic product (GDP) of 
Egypt is USD 301 billion and there is 26 % of the population living under the national 
poverty line of USD 1.56 per day (CAPMAS, 2013). 
 
The health system in Egypt is fragmented with multiple service providers (ISPOR, 
2012). The Ministry of Health (MOH) lies at the center as the main service provider. 
Services are delivered through different establishments managed and overseen by the 
MOH, such as public hospitals, teaching (university) hospitals and hospitals 
belonging to the Health Insurance Organization (HIO), which is the public health 
insurance system.  The coverage of HIO, however, is limited to about 58% of the 
population and covers only employees of the public sector (HIO, 2016) 
 
Services in government facilities, including medicines, are provided either for free or 
against a small fee. Those who do not have insurance coverage can benefit from the 
Program for Treatment at the Expense of the State, which was initiated by the 
government with an independent budget (ISPOR 2012). 
The number of pharmaceutical outlets is around 70,000 nationwide (Ministry 
of Health website, 2016). 
 
Pharmaceutical Industry  
Pharmaceutical industry infrastructure and historical expertise has developed since the 
late 1930s (Holdipharma website, 2016).  The number of pharmaceutical factories is 
144, and the toll companies are around 1200 (MOH, 2016). These companies belong 
to three categories: (1) public sector companies; (2) local private sector companies; 
and (3) multinational corporations (MNCs). Public sector pharmaceutical companies 
operate under the umbrella of the Holding Company for Pharmaceuticals, Chemicals 
and Medical Appliances (HoldiPharma website, 2016).  
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Egyptian pharmaceutical market reached a value of EGP17.6bn (USD2.491bn) 
in 2014, and increased by 7.2 %( 6.7% in local currency and 3.4% in US dollar terms) 
to reach EGP18.937bn in 2015 (Business Monitor International, 2015 Q2).  
The market comprises both the private market (pharmacies and private 
hospitals) and the public market (government hospitals and healthcare centers).  
The distribution of the sales value in 2011 according to ownership type shows that the 
market is relatively concentrated. In 2011, Herfindahl-Hirschman Index (HHI)5 
calculated by Abdelatif (2013) equaled 390.04, that was considered a relatively low 
concentration level of the market in big companies. That is pharmaceutical market has 
higher return on investments for big companies with higher market share, while it is 
low for small companies with lower market share.  
                                                             
5 HH1: is an indicator of the amount of competition among firms in industry according to 
their sizes. It is calculated by summing the squares of the market shares of the firms within 
the industry (usually limited to the 50 largest firms) then the result is proportional to the 
average market share. Increases in the Herfindahl index generally indicate a decrease in 
competition and an increase of market power, whereas decreases indicate the opposite.  
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Figure 1: Pharmaceutical market shrare by company ownership  comparison 
2010-2011 
 
(Abdelatif, 2013) 
 
Figure 2: Pharmaceutical market share by company size (size by sales value) 
 
(Abdelatif, 2013) 
 
Regulatory Framework 
The national medicines policy for Egypt was last updated in 2005 (WHO, 2011), 
however there is no clear implementation or assessment plan for it.  
The Egyptian authority responsible for control of medicines is represented in the 
Central Administration of Pharmaceutical Affairs (CAPA) under the Ministry of 
Health (MOH). CAPA comes at the forefront of drug regulation being mandated with 
critical responsibilities such as Registration, pricing of medicines, and inspection of 
pharmacies and manufacturing facilities. The CAPA hosts departments for 
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Registration; Licensing and Pharmacists’ services; Inspection and Control; and 
Importation and Exportation. Figure 3 shows the organogram of CAPA where two of 
the main departments are the medicines registration and medicine pricing. 
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Figure 3: Central Administration of Pharmaceutical Affairs (CAPA) organization chart 
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Medicines Registration  
Registering medicines in Egypt is considered one of the first access barriers because 
of the involvement of multiple committees and application reviews prior to MA is 
granted. Egypt’s public pharmaceuticals registration process on transparency score is 
6.03 using the WHO methodology for measuring transparency (WHO, 2015).  
According to the report, low scores are related to problems of transparency in 
registration and pricing. 
 
Registration of pharmaceuticals in Egypt follows what is called a “box” system. In the 
"box" policy, every dosage form (tablet, vial, syrup, suppositories, drops... etc.) of any 
active pharmaceutical ingredient has a definite number of similar products to be 
registered. The number of similar products for any API in specific dosage form is 12 
products called "Box", and is composed of one brand product, and 11 generic 
products (10 locally manufactured generic products and 1 imported generic product).  
The brand product is the medicine owned by one company that did research and 
development on the drug molecule and had its first clinical trials and approvals. The 
box registration policy was introduced in 2009 by enforcing the ministerial decree 
296/2009 regulating the human medicines registration. The aim of this decree was to 
encourage the local investment by allowing 10 locally manufactured generic products 
to compete in the market and direct the market resources towards the neglected 
medicines (i.e.: empty medicines boxes) where no competing companies are investing 
their resources. Only one imported generic per box is allowed to be registered.  
A bioequivalence test is required as one of the registration steps. It considered as a 
proof of therapeutic equivalence to be provided in case of generic product. This test 
ensures its efficacy is within an acceptable range to the originator/brand. Acceptable 
ranges are usually between 80-125% of the Area Under-the-Curve6 (AUC) in most 
guidelines. Products with low therapeutic index (i.e.: with high toxicity probability) 
acceptable ranges are between 95%-115%. (Abdelatif et al, 2013) 
 
Currently ministerial decree 425/2015 is regulating the medicines registration and 
following the same "box" policy. It differs in some technical application through the 
                                                             
6 A plot of concentration of drug in blood plasma against time. The area is computed starting at the 
time the drug is administered and ending when the concentration in plasma is negligible. 
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registration process enhancing the registration period and used parallel pathways 
instead of consecutive approvals.  
 
While it is not guaranteed that all registered products will be available on the market 
because of the pricing policy applied, the decree 425/2015 cancels the registered 
medicine if not marketed after granting the MA by 18 months. . In case a product is 
registered, but gets priced too low which does not satisfy the producer, this will allow 
for ensuring the availability of an adequate number of products per pharmaceutical 
generics to replace the dropped medicine. 
Medicine pricing policy in Egypt  
 
Historically, a strict obligatory pricing policy has been implemented with regulation 
of profit control, with the aim of making medicines affordable to the lowest 
socioeconomic segments of the population. 
 Pricing History  
Since the 1960s, medicine pricing was subject to special procedures to guarantee 
affordability. Pricing was mandated to the Egyptian General Foundation of 
Pharmaceuticals and Chemical Products, which took the full responsibility for the 
pharmaceutical system at the time (Wanis, 2014).  
A special Pricing Committee was established by the Minister of Health to set prices or 
mark up for locally produced and imported pharmaceutical products. 
Later, cost-plus and mark up regulation were put in place by two ministerial decrees 
in 1990 and 1991. This pricing system was based on economic cost. It specified profit 
margins for producers, distributors and pharmacists, and presented a detailed 
breakdown of the pricing process under direct costs, indirect costs, profit margin of 
the manufacturer, discount of expedited payment and distribution expenses, public 
retail price and revisions of product prices (MOH, 2016).  
 
In 2009, decree 373/2009 distinguished between branded and generic medicines. 
Branded, or innovator, medicines refer to those primarily produced by MNCs; and 
they are either imported or produced locally under license, whereas generic medicines 
refer to locally produced off-patent medicines. Branded medicines were priced at 10 
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% less than the least price of a country where they are marketed. The decree provided 
a guiding list of 36 countries to use as reference countries. Generic medicines were 
priced at a mark down percentage of the price of the branded medicine. This pricing 
decree has been replaced by decree 499/2012.  
Current Egypt pricing policy  
Ministerial decree 499/2012 was issued in 2012 and still in place setting the pricing 
regulations. 
The current policy adopts a combination of External Reference Pricing (ERP) and 
regulation of mark-ups and profit margins for the stakeholders in the supply chain. 
Reference countries used refer to their prices are the same list used in the decree 
373/2009. Table (1) shows the list of reference countries used for external reference 
pricing in Egypt. 
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Table 1: List of reference countries used in Egypt external reference pricing 
 
 
According to the pricing decree 499/2012, price of the innovator product is 
determined according to the "lowest public" price in all countries in which innovator 
product is marketed. If the innovator product is marketed in less than 5 Countries, the 
price is determined according to either 1-comparative study, or 2- according to the 
lowest public price in all countries in which the innovator product is marketed. 
The pricing of a Generic Product in this policy is as follows: 
-The first five generic products are priced at 65% of the innovator product price. 
-The rest of the generic products are priced at 60% of the innovator product price. 
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Within a given “box” of generic products, the pricing committee tends to strictly 
observe descending prices depending on registration date. The later the registration 
date, the lower the price given to the generic product. It is common to have long 
waiting lists of other products for registration in case a product dropped of the “box”. 
This happens in case a pharmaceutical company registers a product and does not 
market it for a period of 18 months.  
 
Limitations of the ERP in Egypt pricing policy is that its use may involve incorrect 
choice of reference countries, i.e. countries with substantially different market 
structures or prices (e.g. a low-income country using high-income countries as the 
sole reference leads to inflated prices).  Moreover, price information is not always 
available, and the available prices are often heterogeneous and often difficult to adjust 
them to obtain the required type of price. Finally, transaction prices are elusive – the 
prices that countries can access are often not real but virtual list/catalogue prices. True 
prices may be concealed for purposes such as rebates or risk-sharing arrangements, 
and sometimes launch delays and non-availability of new medicines. 
 
Medicines prices contain the mark-ups that represent profitability margins for the 
pharmaceutical supply chain stakeholders, and in the same time affordability to 
patients.  
 
Egypt pharmaceuticals and Intellectual Property 
 
Egypt is a member in world trade organization, and a signatory to the Trade-
Related Aspects of Intellectual Property Rights (TRIPS) agreement. This agreement 
protects the innovations by patenting the new molecule of drug for a period of time so 
that no other generic or equivalent medicine could be on the market. This mainly is to 
protect the free trade and the profitability of the innovator company.  
Stages preceding the marketing and approval of new drug molecule involve 
the preclinical and Clinical trials on animals and humans that may range from 12 to 17 
years. Filing of patents to protect the data is mandating all other WTO member 
countries to reject any goods that may violate the patent of the original product. 
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While medicine is a commodity used of public health protection, it was a great 
concern to be included under the TRIPS agreement. Doha rounds had successfully 
resulted in some flexibility to ensure protection of public health as will be explained 
in some later parts of this thesis.  
Patents in some cases create monopolistic behavior for the innovator company 
world-wide especially after one incident relates to the HIV treatment (Kiddell-
Monroe, 2014). In 2000, Médecins sans Frontières (MSF) innovated an HIV medicine 
that was priced at $ 15,000  (Kiddell-Monroe, 2014). By implementing competition 
policies and epidemic state of African and Sub-Saharan countries, MSF decreased its 
price in response to more generic competition and allowed from 400,000 cases treated 
in 2003 to 1.6 million cases treated in 2006 (WHO, 2006). Consequently, the IP is a 
public health concern.  
The IP issue is Egypt is handled by the Egyptian Patent office (EGYPO) which 
is the entity responsible for receiving, assessing and making decision on patent 
applications filed in Egypt ( Egypt as other countries doesn’t recognize patents granted in 
other countries, to be granted patent for your product protection you have to file a local 
application). Egypt had issued law number 82 in 2002 complying with the TRIPS 
agreement signed in 1995.
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Different pricing policies 
The WHO had defined some governments interventions for regulations of prices. 
Table2 illustrates some of these interventions  
Table 2: Definitions for pricing regulations as government interventions 
Policy/ intervention Definition 
Regulation of markups in 
the pharmaceutical supply 
and distribution chain 
A mark-up represents the additional charges and costs that are applied 
to the price of commodity in order to cover overhead costs, distribution 
charges and profit. In the context of the pharmaceutical supply chain, 
policies might involve regulation of wholesale and retail mark-ups as 
well as pharmaceutical remuneration. 
Tax exemptions/reductions 
for pharmaceutical products 
 
There are two main categories of tax: direct tax, levied by governments 
on the income of individuals and corporations, and indirect taxes, 
added to the prices of goods and services and collected through the 
businesses that provide them. Direct taxes, along with social security 
taxes, generally make up about two thirds of total government revenue 
in high-income countries. 
In low-income countries, indirect taxes, on international trade or on the 
purchase of goods and services, are the major sources of government 
revenue. Policies might involve the reduction of taxes on medicines, or 
the exemption of medicines from taxes, particularly sales taxes. 
Application of cost-plus 
pricing formulae for 
pharmaceutical price setting 
Cost-plus pricing is a method for setting retail prices of medicines by 
taking into account production cost of a medicine together with 
allowances for promotional expenses, manufacturer’s profit margins, 
and charges and profit margins in the supply chain. 
Use of external reference 
pricing 
 
External reference pricing (ERP; also known as international reference 
pricing) refers to the practice of using the price of a pharmaceutical 
product (generally ex-manufacturer price, or other common point 
within the distribution chain) in one or several countries to derive a 
benchmark or reference price for the purposes of setting or negotiating 
the price of the product in a given country. Reference may be made to 
single-source or multisource supply products 
Promotion of use of generic 
medicines 
 
Generic medicines are produced and distributed without patent 
protection. Promotion of the use of quality assured generic medicines is 
a method of managing pharmaceutical prices. The various approaches 
used include facilitated market entry of generics, generic substitution by 
dispensers, ERP, strategies to foster competition in the market, and 
schemes to encourage use of generics among providers and consumers. 
Use of health technology 
assessment (HTA) 
 
The International Network of Agencies for Health Technology 
Assessment defines HTA as “The systematic evaluation of properties, 
effects, and/or impacts of health care technology. It may address the 
direct, intended consequences of technologies as well as their indirect, 
unintended consequences. Its main purpose is to inform technology-
related policymaking in health care. HTA is conducted by 
interdisciplinary groups using explicit analytical frameworks drawing 
from a variety of methods.” HTA in relation to pharmaceuticals 
encompasses evaluations relevant to price setting or pricing policies. 
(WHO, 2015) 
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Reference Pricing 
An intervention usually set by governments to regulate prices of marketed 
medicines. As indicated by its name, a price for the medicine is set according to the 
price of the same medicine or similar one in another country or organization (Acosta, 
2014). 
Reference may be internal or external. In internal reference pricing, the medicine 
referred to is marketed within the same country. This pricing policy is used for 
reimbursement systems and for insurers' organizations.  
In internal reference pricing and reimbursement policies, the reference price is set 
equal to one of the following (Verijens, 2010):  
1) The lowest price defined in the cluster of medicines grouped together as in 
Australia, 
2) The average of the prices of all medicines included in the cluster as in 
Netherlands, 
3) The average of the lowest two prices in the cluster as in Denmark, The highest 
price generic drug in the cluster as in Portugal, and  
4) by estimating regression model for all prices of medicines in the cluster as in 
Germany. 
External reference pricing is setting the price of the medicine marketed in 
another country other than the intervening policy-setting country. In this case, the 
country is called reference country. 
External Reference Pricing: The price of medicine in one country is set according to 
its price in another country. The country setting the price is called referee while the 
country with the established referred-to price is called reference country. Countries 
usually select other countries to refer to their prices based on some criteria. Being in 
the same geographic region, sharing borders, close socioeconomic characteristics, 
close income level, similar health systems. The price selected is usually the ex-factory 
price from the reference country. Mark-ups are then added according to the country 
policy in regulating the supply side margins (Espin et al, 2011). Some countries are 
usually used as reference based on the availability of price information, ease of access 
to public databases or lower prices globally.  
This may well result in problems in the availability and affordability of some 
medicines in some countries, both within and particularly outside the OECD, unless 
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policy makers change pricing and reimbursement policies to adapt to the new market 
dynamic. (OECD, 2008) 
In some countries, both internal and external reference pricing take place. When 
pricing a newly launched brand medicine in country for the first time, it uses the 
external reference pricing. Generic pharmaceutical then are priced for local marketing 
using the internal reference pricing. Margins and mark-ups are then added and 
adjusted for final price. 
Table (3) shows the different adoption of ERP for pharmaceuticals and specific 
application to defined category of medicines (WHO, 2015). 
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Table 3:Detailed External reference pricing followed in some countries; shows authority, products regulatence countries, and type of 
price used 
(WHO, 2015) 
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Index Pricing 
A pricing policy used mainly for reimbursement systems in which a group of similar 
medicines are priced according to the weighed-average of the therapeutic group of 
medicines. The reimbursement price is then defined and revised periodically to allow 
for improvement in the reimbursement price. The outlet is reimbursed for the indexed 
price when they dispense any medicine in the defined therapeutic group. This system 
allows for companies to lower its prices in a free market price to keep their market 
share of sales and to be on the top priority of dispensed medicines at the outlet. On the 
long run, reimbursement organization will revise index prices lowering the level to 
the actual dispensed medicines. 
 
Maximum prices 
Also called ceiling price, in which a fixed price is set to secure pharmaceutical prices 
that are considered ‘reasonable’ for a given health system. There are different 
approaches to set the maximum prices: negotiated prices, price-caps, cost-plus, price 
comparisons to other countries or to similar products within the same country, or 
price-volume trade-offs (Mossialos 2004).  
This is a cost containment measure that companies are allowed to choose any price 
below this threshold, described as price cap or price ceiling by the WHO 
Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies 
Glossary (PHIS, 2016).  
Profit regulation 
Mark-ups7 can be regulated by the government or negotiated between the government 
and the companies, as under the Pharmaceutical Price Regulation Scheme (PPRS) in 
the UK (Borrell 1999). This can indirectly influence drug prices by setting profit 
limits. The PPRS is based on periodic negotiations between the Association of the 
British Pharmaceutical Industry and the Department of Health. It is reviewed every 
few years (PPRS 2009). If profits exceed a certain level, the company must reduce 
profits by cutting prices, delaying or restricting previously agreed future price 
increases, or repaying the excess profit to the Department of Health. 
                                                             
7 Margins of profit the company or the stakeholder has and reflect the Rates of return on the 
investment. 
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Stepped price model 
This policy is related to medicines with patents. Prices can be adjusted when patents 
expire. In Norway, a stepped price model was introduced in January 2005. In this 
model a maximum reimbursement price is set for drugs (both branded and generics). 
The maximum price is automatically reduced in steps following generic competition 
after patent expiry (Norwegian Pharmacy Association, 2008). The size of the price cut 
steps depends on the sales volumes prior to establishment of generic competition and 
the time since competition was established (Festoy 2008). 
The competition policy pricing scheme  
In which the market is open and companies can freely price their medicines. 
Competition in this case should be protected by laws and regulations, e.g.: 
competition law and specialized organizations should be powerful enough to pursue 
such laws and enforce it. Not all countries can feasibly apply this scheme without 
health care coverage and reimbursement system, and adequate independent and 
functioning jurisdictional system in place with powerful enforcement authorities in 
cases of violations. In this case the cost for anti-competition measures can be high 
regarding the patient health and availability of medicines. (Hawkins, 2011) 
Other pricing policies 
These may include price negotiations, volume-based pricing, procurement and rebate 
policies.  
When negotiating the price, several considerations can be taken into account: 
costs of products, prices in comparable countries, therapeutic value of the product, 
evidence of clinical effectiveness and safety, and price-volume arrangements. 
Under a price-volume arrangement, the agreed drug price is based on a 
forecast volume of sales. If the actual volume exceeds the forecast, the drug price 
usually has to be lowered. Pricing regulation may apply to initial or posterior prices 
once products are marketed, and can be based on prices for the same product in other 
countries or on the costs of similar treatments for the same indication (Espin, 2007). 
Reimbursement decisions and pricing for new drugs can also be based on economic 
evaluations of the new treatment compared with existing options (Espin 2007). 
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Figure 4: Map showing counries using ERP and their reference countries 
 
(WHO, 2015)
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Socioeconomic Factors  
 
Egypt has strong socioeconomic class stratification, with large income gaps. This 
stratification is manifested in housing and sanitary conditions, literacy levels, health 
awareness, working conditions and, accordingly, types of prevalent diseases. Social 
implications of the above economic factors can act as barriers to accessing medication 
(Wanis, 2009). 
Egypt Gross Domestic Product (GDP) was worth 301.5 billion US dollars in 2014. The GDP 
value of Egypt represents 0.37 % of the world economy (Trading and economics website, 
2013).  Although Egypt GDP per capita is USD 3,198 in 2014 (WB, 2016), it is not indicative 
of the average income level, as there are 26.3 % under the poverty level (WHO, 2002). There 
is 32.2% of rural population living at the national poverty line8 (WB, 2010). There is 
noticeable bias in resource allocation towards higher income groups.  
Egypt consists of twenty seven governorates; five of which are urban; Egypt, Alexandria, 
Suez, Ismailia, and Port Said. The remaining twenty two governorates are characterized by 
urban and rural areas. Nearly 40% of Egyptian population lives in urban areas (Figure 5: 
Egypt Rural population as percent of total population); Cairo and Alexandria are among 
the world's most densely populated. 
 
Government healthcare services tend to be through big programs, which unintentionally favor 
urban populations. It has been argued that ‘‘access to medical services in rural areas is limited 
and selective’’ in developing countries (Bapna et al., 1996).  
Medication costs constitute around 53% of average health care expenditure (CAPMAS, 2013) 
shown in Figure 7: Percentage distribution of Expenditure on Healthcare 2012/2013 . 
With inadequate insurance coverage and high out-of-pocket health expenditure, income level 
becomes a major determinant of access to medication. Rural areas are at higher risk of facing 
inadequate access to healthcare due to their higher percentage of poverty. 
 
Adult literacy rate is 61%; illiteracy is particularly high in rural areas (WHO, 2005). Lack of 
health awareness, negligence and reluctance to seek medical advice indirectly influence 
access to healthcare services and, accordingly, necessary treatment.  
 
                                                             
8 Poverty line was defined by CAPMAS in 2013 as EGP3900 annual income (CAPMAS, 2013). 
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Figure 5: Egypt Rural population as percent of total population 
 
(CAPMAS, 2013) 
 
 
While the poverty headcount rate in rural population was around 32% of rural areas in 
2012, the rural areas constitute more than 67% of poverty that represent more than 
quarter, 26.3%, of the Egyptian population. That is quarter of Egypt population are poor 
and more than two thirds of this poverty lies in rural areas. 
Figure 6: Poverty percentage of rural population 
(Trending Economics, 2016) 
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Table 4: Percentage of poor among socioeconomic areas in Egypt 
Unit : (%) 
Item 2012/2013 2010/2011 
Urban governorates 15.7 9.6 
Lower Urban 11.7 10.3 
Lower Rural 17.4 17.0 
Upper Urban 26.7 29.5 
Upper Rural 49.4 51.4 
Boundary 
governorates 
24.2 36.9 
Total Egypt 26.3 25.2 
(CAPMAS, 2013) 
 
CAPMAS published the household survey for 2013 that showed expenditure classes 
distribution. It was amazingly found that the highest spending class of EGP12,000/person 
or more annually is 6% of the population. The urban population has 11.8% lies in this 
high spending category, while only 2% of rural population are there.  
The highest percentage of population spend EGP4,000– EGP5,000/ person annually. On 
the contrary, population had 38% and 31% of rural and urban residents respectively are 
located in this class. (CAPMAS, 2013) 
The expenditure items classification in 2013 showed that the individual spending on the 
healthcare item was higher in rural population, 10.1%, relative to the urban population, 
9.5% (CAPMAS, 2013). This shows the higher burden for health care costs in the rural 
areas in addition to the higher poverty levels indicated in lower expenditure 
classifications.  
The segmentation of health care expenditure shows that 53% are spent on medicines, 
while the rest is used for physician visits and inpatient care.   
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Figure 7: Percentage distribution of Expenditure on Healthcare 2012/2013 
       
(CAPMAS, 2013) 
 
As poverty prevails more in rural areas, as the income of the rural population increases, 
they will be in a better position to demand better health, education and other social 
services and pay for them in the longer run. What is obvious, therefore, is that being poor 
is very much a characteristic of residing in rural Egypt and thus having less access to 
public goods and services 
 
Meanwhile, about 57% of the total population in Egypt lives in rural areas, where 
poverty prevails. About 70% of the poor and very poor live in rural areas. Within these 
realities of the Egyptian economy, enhancing sustainable agricultural and rural 
development as a means to reduce poverty and food insecurity within the expected 
climate changes is a prerequisite for sustainable social and economic development and 
hence should be considered as a social and political priority for Egypt (Handoussa, 2010). 
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Table 5: Estimated Household distribution according to wealth index 
Weather Index 
Place of Residence 
Total % 
Urban% Rural % 
Lowest 6.8 30.8 20 
Lower Middle 11.7 26.5 19.8 
Middle 17.2 22.6 20.2 
Upper Middle 27 14.3 20 
Highest 37.3 5.8 20 
Total 100 100 100 
 (USAID, 2010) 
 
Table 6: Percentage distribution of annual individual consumption by main 
expenditure group and socioeconomic area of residence 
Unit : (%) 
      
Expenditure Group 
2012/2013 2010/2011 
Total Rural Urban Total Rural Urban 
Food and drink 36 39.7 32.5 39.9 45 35.6 
Beverage and Tobacco 3.3 3.6 3.1 3.4 3.8 3.1 
Clothing and textiles 5.7 6.2 5.3 5.3 5.5 5 
Housing 18.6 17.2 19.9 18 16.9 18.8 
Furniture and 
maintenance 
4.3 4.4 4.1 3.9 3.8 4 
Healthcare services 9.8 10.1 9.5 8.1 8.3 8.1 
Transport 5.8 4.7 6.9 5.3 3.8 6.6 
Communication 2.7 2.2 3.3 2.5 1.9 3 
Entertainment 2 1.7 2.2 2.2 1.5 2.7 
Education 3.7 2.3 5 3.9 2.2 5.4 
Hotel and Restaurants 3.6 3.1 4.1 3.5 3.2 3.8 
Miscellaneous goods and 
services 
3.3 3.1 3.4 2.9 2.7 3 
Total Annual Household 
Expenditure 
100 100 100 100 100 100 
(CAPMAS, 2013)  
 
Adequate health care coverage and insurance is basic need that the State 
guarantees for all citizens (under the latest Egyptian Constitution, article 18). Article 
238 of the constitution enforced the health care budget to reach 3% of the GDP when 
it used to be 1.6 % of GDP in 2013/2014 fiscal year.  
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Figure 8 : Egypt GDP per capita 
(World Bank, 2016) 
 
 
Non-Communicable Diseases 
 
Non-communicable diseases (NCDs) are a global health crisis. By 2030, 75% of the 
world’s deaths will be caused by cancer, diabetes, CVS and lung disease. Not only are 
NCDs a global health crisis, they also reveal a crisis of global health inequality: most 
of NCD deaths reported worldwide occur in low- and middle-income countries 
(LMIC), (WHO, 2008). 
The purpose of this study acquired its importance from the highest burden NCDs in 
Egypt. NCDs account for 82% of deaths and 67% of premature deaths in Egypt 
(WHO, 2016). NCDs with highest burden in Egypt are Cardiovascular (CVS) 
diseases, Diabetes Mellitus (DM), and respiratory (Asthma,COPD), and Renal 
diseases.  
NCDs kill 38 million people each year globally.  Almost three quarters of NCD 
deaths - 28 million - occur in low- and middle-income countries (LMIC). Sixteen 
million NCD deaths occur before the age of 70; 82% of these "premature" deaths 
occurred in low- and middle-income countries (LMIC), (WHO, 2016).  
Cardiovascular diseases account for most NCD deaths, or 17.5 million people 
annually, followed by cancers (8.2 million), respiratory diseases (4 million), and 
diabetes (1.5 million). These 4 groups of diseases account for 82% of all NCD deaths 
(WHO, 2016).  
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In Egypt, the aggregate labor supply is around 19% below its potential, driven by lost 
employment and reduced numbers of hours worked by those reporting chronic 
conditions, implying an overall production loss of roughly 12 percent of the country’s 
GDP (Rocco et al, 2011). 
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Research Question 
 
According to the World Health Organization, access to medicines is measured 
by two factors, affordability and availability (WHO, 2003). Linking the pricing policy; 
affordability on the one hand, to the socioeconomic influences; availability on the 
other hand, will be an important milestone for setting any pharmaceutical regulation. 
Affordability and prices survey was conducted in 2013 and found that mostly all 
medicines on the EML List for chronic diseases are affordable (HAI, 2014) 
Non-Communicable Diseases (NCDs) affect adults in their productive years, 
require long term treatment and often cause disability. They can have more severe 
economic consequences for the individual and his or her family,—including decrease 
or loss of household income, impoverishment, loss of savings and assets, and reduced 
opportunities—than other illnesses. While the burden of NCDs is rising, it can 
constitute a major health challenge of access to affordable NCDs medicines. 
From a social equality perspective, all socioeconomic classes should have the same 
privilege of access to brand medicines as well as its generics. The prescribing behavior 
of the physician may be influenced by the socioeconomic class and geographic 
location of the patient due to the difference in prices of the brand and generic 
medicines. 
The study of availability of both brand and generic medicines will certainly 
reshape the policy for registration, pricing, and pharmaceutical trade; import and 
export. 
This research will reveal some of the market behavior in different socially 
distinct geographic areas. To what extent of urban and rural conditions affect the 
medicines supply. The null hypothesis for the research is "in comparison to Brand 
medicines, their generics are equally available in both urban and rural areas". The 
alternative hypothesis is "In comparison to Brand medicine, their generics will be 
more available in rural rather than urban areas". Some actions may be required for 
allowing equal availability of brand and generic pharmaceutical products.  
With extensive review of the literature, and up to our knowledge, there is no 
Egyptian study had been done before for the analysis of the urban and rural 
determinant for market supply of generic and brand medicines in Egypt. 
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Conceptual Framework 
 
This research paper investigates the relationship between the pharmaceutical 
supply of the medicine types, and the rural and urban areas where patients reside. The 
association has been studied before in different countries other than Egypt. Prior 
studies were done considering the consumption perspective; i.e.: the demand side of 
the market. Supply side was not investigated in most studies. While firms with brand 
products have higher prices usually target those higher socioeconomic classes, rural 
areas are targeted by generics suppliers. Deliberate choice of either brand or generic 
by patients may be absent due to the role of supply side as a determinant of the market 
consumption.  
While Acosta et al (2014) and Stargardt (2009) illustrated that reference price 
for reimbursement organization does not affect the patient health at all, it only affect 
the other competitor companies to lower their prices, Khan et al (2015) showed that 60 
% of low income household in 18 LMIC cannot purchase the medicines not only due 
to the financial constraint but also due to several socioeconomic determinants where 
we will investigate the solid relation between the supply and urban/rural preference of 
the outlet. And most important, Skipper et al (2015) concluded that patients 
socioeconomic characteristics differ in probabilities of choosing brand product 
medicines by 2.9% higher for those employed patients rather than unemployed. 
As pricing policy of pharmaceutical differentiates between brand medicines 
and its generics, brand medicines have higher prices than its generics. Suppliers will 
then be able to market their medicines to the urban areas having higher socioeconomic 
context rather than rural areas with lower socioeconomic profile. The relationship 
between the brand/generic and price is already established. So, we will study the 
relationship between brand/generic medicines with its availability/supply in 
urban/rural areas in Egypt as a result of the pricing policy followed as shown in Figure 
9: Conceptual framework for this research. 
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Pricing Policy in Egypt 
Brand medicine 
(Higher price) 
Generic medicine 
(Lower price) 
Availability of both types 
of NCD medicines in  
Relation to different 
areas 
Urban Areas 
(Higher socioeconomic 
profile) 
Rural Areas 
(Lower socioeconomic 
profile) 
SUPPLY 
DEMAND 
Consumption 
 (in absence of Social Health 
insurance covering all 
population) 
Characterized by inequity 
Our study focuses on this 
relationship at the supply 
side 
Figure 9: Conceptual framework for this research thesis 
Brand and Generic Medicines Supply to Socioeconomic Areas of Egypt  
 
33 
 
Chapter 2: Literature Review  
 
While most studies in the literature controlled for very comprehensive set of political 
and socioeconomic covariates (Vatter et al, 2003). Empirical studies of the 
socioeconomic impact on consumption of brand and generic medicines have not 
reached consistent conclusions. 
 
For all drugs in Belgium, the reference price is based on a simple reduction in the ex-
factory price of the brand drug then increased by the distribution and pharmacy 
margins to obtain the public price (Farfan-Portet et al, 2012).  
 
In a study that is relevant to our research, one of the important findings that Farfan-
Portet et al (2012) had is the positive relationship between the use of a generic drug 
and a lower socioeconomic status. The characteristics of the drugs may also be 
important; whether acute diseases requiring treatments for short time periods, or drugs 
for serious complex and chronic conditions requiring the prolonged treatment periods.  
 
Farfan-Portet et al (2012) recommended that for mitigating the socioeconomic 
determinant in the choice of brand versus generic medicine, that physicians should be 
aware of the minimum percentage of low cost prescriptions. A color code was 
introduced to the National Drug Information Center to increase awareness of the 
excess prices paid over the reference prices set by the reimbursement/insurance 
organization in addition to publishing an easily accessible price comparisons for all 
drug groups on the website of the Information Center, and the third-party payer (the 
National Institute for Health and Disability Insurance -RIZIV/INAMI) 
 
Switching between brand and generic medicines is not allowed in Belgium for 
pharmacists except in case only when the prescription is written using the 
International Nonproprietary Name (INN) of the drug, then pharmacists are allowed 
to deliver a low-cost drug. It is only 7% of prescriptions that were written using INN 
in 2009. (Farfan-Portet et al, 2012).  
Only four papers analyzed the impact of reference pricing according to the 
socioeconomic and patient characteristics (Verijens et al, 2010). Verijens et al (2010) 
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analyzed the reference price system in different countries based on three major 
attributes to which fundamental use of the system differs. These three objectives were 
what medicines are to be covered under the system, which price used as reference, 
and finally incentives for the use of lower cost medicines.  
While New Zealand, Australia and Netherland apply the grouping of Anatomic 
Therapeutic Chemical Classification9 (ATC-4) level for reference price (that is the 
pharmacologically equivalent molecules are grouped together), Denmark, Portugal , 
France and Spain apply the ATC-5 level grouping (all medicines have the same active 
pharmaceutical ingredients; brand and generic) of reference price application. Italy, 
Hungary and Canada apply the reference system to cluster grouped according to 
ATC-3 level (the therapeutically equivalent while pharmacologically different 
molecules are grouped together)  
 
While reference price system contributes to the improvement in health expenditure 
savings in British Columbia, Canada, patient socioeconomic characteristics were not 
different when using the health services. RPS however, induced the lower 
socioeconomic patients for tendency towards the use of reference low cost 
pharmaceutical products rather than higher socioeconomic patients (Schneeweiss et 
al., 2003).  
 
In one other important working paper, Rischatsch and Trottmann (2009) showed the 
relationship between patient deductibles under their insurance coverage to the use of 
generic medicines. The higher the deductible, the higher the tendency for using lowest 
cost generic medicine. Patients with higher socioeconomic background have lower 
sensitivity to the higher price of brand medicines because of the lower marginal utility 
of their income. 
 
Skipper et al (2015) found that socioeconomic characteristics of both patients and 
doctors to have low explanatory power. Patients socioeconomic characteristics differ 
in probabilities of choosing brand product medicines by 2.9% higher for those 
                                                             
9 Pharmaceutical coding used for classification system: It divides drugs into different groups according 
to the organ or system on which they act and/or their therapeutic and chemical characteristics. Each 
bottom-level ATC code stands for a pharmaceutically used substance, or a combination of substances, 
in a single indication. One drug can have more than one code 
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employed patients rather than unemployed. Introduction of generics and their inherent 
impact on the price of treatment seems to explain roughly one third of the variation in 
drug choice (Skipper et al, 2015). 
 
Khan et al (2015) found that in Low- and Middle-Income Countries (LMIC) there is 
risk of negative health outcome due to the decreased access and availability of 
medicines used in cardiovascular conditions. They showed that 60 % of low income 
household in 18 countries cannot purchase the medicines not only due to the financial 
constraint but also due to several socioeconomic determinants as health literacy and 
general awareness, and provider competency. 
 
Schneeweiss et al. (2002) found that compared to high income patients, those on low 
and middle income were more likely to switch to the less expensive drug (the 
reference drug) or to switch from the expensive antihypertensive drug (having a 
reference supplement) to another antihypertensive therapy. However, the authors also 
mentioned that before and after the introduction of the RPS stopping any 
antihypertensive treatment was more likely for low income patients. 
 
Schneeweiss et al. (2003) analyzed the use of dihydropyridine calcium channel 
blockers; an antihypertensive medicine, and the use of health services after the 
introduction of the RPS. They found that low-income patients had on average a higher 
probability to switch to the no-cost dihydropyridine (reference drug) or to switch from 
the expensive dihydropyridine drug (having a reference supplement) to another 
antihypertensive therapy (nitrates). Patient characteristics were found not to be 
associated to the impact of the RPS on physician visits, hospitalization and admission 
to long-term facilities. 
 
Ibrahim et al (2012) recommended that generic medicines used for hypertension 
should be available in the public primary care level and that scrutiny should be 
followed to ensure the quality control of their dispensing and efficacy in relation to 
other drug interactions.  
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Recent studies searching for the effect of pricing mechanisms and reimbursement 
policies on people's health and adverse events are lacking. Most internal reference 
pricings and index pricing used for the lowering of the medicines cost to insurers and 
reimbursement organizations (Acosta et al, 2014). The internal reference pricing 
largely indicated savings on health spending and shift towards the reference-priced 
medication, whether it is brand or generic. Mostly, pharmacy outlets tend to dispense 
the generic medicines within the set group of medicines under the index pricing 
scheme to maximize the benefit of reimbursement (Acosta et al, 2014).  
While some countries utilize the internal reference pricing for pharmaceuticals, they 
do not set prices out of the reimbursement systems.  
 
In terms of financial accessibility, the internal reference price system in Belgium does 
not impose an unbalanced financial burden on low-income patients. However, some 
patients are still bearing the cost of using brand medicine when a cheaper alternative 
is available. Moreover, there are prescriptions entailing a reference supplement. This 
is particularly important in a system of generic reference pricing with narrowly 
defined clusters where potential differences in clinical effectiveness of generic and 
brand drugs can be regarded as negligible (Farfan-Portet, 2012) 
 
Perception of equivalent generic and brand medicine is important key concept for 
switching to any of both. Kohli and Buller (2013) studied the consumer purchasing 
pattern for generics and brand Over-The-Counter (OTC) medicines in US. The study 
concluded that the main factor for the purchasing pattern for OTC medicines is the 
medicine price. Lower price OTC medicines were believed by 90% of participants to 
be of equal quality and safety as long as it undergoes the FDA approval. 
In Egyptian pharmaceutical regulatory system, bioequivalence was introduced as key 
step in medicines registration in 2008 (Abdelatif et al, 2010). This test ensures that 
both brand and generic medicine of the same active pharmaceutical ingredient have 
the same efficacy, potency and bioavailability within the acceptable standard range.  
In France, pharmacists have the financial incentives to dispense generic medicines 
(Venjens, 2012). Switching between generic and brand is a pharmacist right and 
patient consent is required except in cases prohibited by the physician when the 
medicine has a narrow therapeutic index or when guidelines state that medicine to 
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begin with is to maintain on for the course of treatment. This might be applicable to 
NCD medicines except for those with narrow therapeutic indices as mentioned. 
(Venjens, 2012). He also claimed that implementing reference price system was not 
followed in reduction of branded pharmaceutical products prices. 
Although the quality of both brand medicines and its generics are 
controversial, Badjatya et al (2013) claimed that once USFDA approved a generic 
drug it means that this generic had undergone rigorous evaluation procedure and 
mentioned that  
"The USFDA requires that generic drugs work as fast and as effectively as the 
original brand-name products", and also "Generic drugs have same onset of action, 
mechanism of action, and release profile to brand drugs" (Badjatya et al, 2013). 
Vaithianathan et al (2015) concluded that for some selected medicines, a set of 
analytical tests done verifying the appearance, identity, assay, impurity, uniformity of 
dosage units, disintegration, dissolution, friability, and loss on drying of a brand 
medicine and its generics. These market surveillance results indicate that all brand 
and generic passed all tests and showed acceptable pharmaceutical quality and low 
biopharmaceutical risk.  
On the one hand, supporter of equivalent quality of both brand and its generics 
claim that any regulatory authority would ensure the equal quality for both medicines. 
On the other hand, Yang et al (2012) revealed that not all tests performed for 
comparison between a brand and its generics is successful. Dissolution and assay tests 
for both medicines may reveal the different formulation of both medicines and, hence, 
different onset of action. However, the importance of exact results are not required in 
most cases as long as therapeutic indication is addressed unless the medicine has a 
narrow therapeutic index and higher toxicity margin that requires extra tests and 
verification of the equivalent therapeutic actions (Yang et al, 2012).  
The USFDA defined the bioequivalence for generics as to have no significant 
difference in the rate of bioavailability of the drug molecule at the site of action for 
both brand and its generic (FDA, 2003). While acceptable range of bioavailability is 
20 percent below and 25 percent above; that is 45 percent variability between brand 
and its generics. Then, as referred to above the medicines with narrow therapeutic 
index have to be closely monitored when releasing copies of brand medicines 
(generics) into the market. 
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Gazzili et al (2010) concluded that reference price tend to reduce the branded 
medicine prices in free markets. When firms with brand pharmaceuticals do not 
respond to the reference price, they allow more market share for generics. They also 
concluded that there is no association between the reference price system (therapeutic 
reference) and the health outcomes. That is no socioeconomic profile was considered. 
 
Abdelatif et al (2013) recommended that Egyptian pharmaceutical market should be 
more open by cancelling the box-policy registration to allow more access to 
medicines. It is the market-derived not government-enforced decision for any 
company with new-entry medicine, whether brand or generic. However, securing 
market supply of pharmaceuticals is considered as national security issue. 
 
Simoens (2009) elaborated that pharmaceutical pricing in Poland is not mandatory for 
firms that are not willing to be included on reimbursement system of the country. 
Patients do not have the incentives to shift from brand to generic or the vice versa 
except for reimbursed reference price. Patients pay their co-payments that exceed the 
reference prices defined by the reimbursement system and no preference for 
purchasing either brand or generic once the physician had prescribed the medicines.  
Some countries, such as France and Italy, regulate drug prices directly through price 
control; others, such as Australia, use Pharmaco-economic (PE) analyses and 
reference pricing to determine the prices of drugs subsidized by the government 
(Danzon, 2000).  
Germany and Japan control prices indirectly through limits on reimbursement under 
social insurance schemes (Danzon, 2000). In The Netherlands, the government 
introduced reference-pricing system in 1991, and wholesalers were forced to lower 
their prices by an average of 20% in 1996 (Gier, 2003). Pricing regulations also seem 
vital, as in many Latin American countries “free schemes of drug prices” have not 
proved effective as a cost containment mechanism. In Guatemala and Peru, prices 
have increased over and above the exchange rate or the consumer price index, and in 
Bolivia the practice of the free market concept has not yielded any benefits 
(Sarmiento, 1995). 
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In India, essential drugs cannot cost more than twice the cost of production, and the 
maximum retail price and local taxes must be included in a drug's final printed price 
(Kumar, 2004). This model follows the “cost-plus pricing” where the prices are 
negotiated between the manufacturer and the national authority, based on raw material 
costs, production costs, marketing costs, and a reasonable allowance for profit. 
 
The entry price for the new drug in the market is an important factor determining the 
other generics prices later on. In Germany, prices are anchored at certain level. 
Although not an external reference price- following country but their prices are 
referred to by other potential markets. This explains why high prices in Germany are 
maintained nevertheless the local market is not influencing the price decrease. It is 
mainly to avoid harming the prices in other markets (Mueller et al, 2013) 
 
Stargardt (2009) illustrated that reference price for reimbursement organization does 
not affect the patient health at all, it  only affect the other competitor companies to 
lower their prices including those brand products if included in the reimbursement 
system. 
 
Similar study was conducted in Sri Lanka showed that availability of brand products 
over private pharmacies is 26% (Dabare et al, 2014).  
Anggriani et al (2014) conducted a study for generic and brand availability. They 
concluded that regulation of medicine prices through generics policy in Indonesia 
promotes the lowering of generics prices while branded products prices are not 
regulated. 
Not only governments have to measure their efforts for improving access to 
medicines, but also private Research and Development (R&D) companies are 
stakeholders. Consensus is required amongst those pharmaceutical companies 
supplying medicines used for treatment of diseases of worldwide concern.  
Kyle (2006) indicated that market access is not a function of the government only. It 
is a shared substantial effect of both the local market and the company characteristics 
and willingness to launch its product in certain market. Kyle concluded that price 
controls have an influence on delayed launch of R&D companies in other foreign 
market. While shared borders and language is preferably enhancing the quick launch 
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of the new pharmaceutical product, it remains the company tendency to provide 
treatment for certain population and profitability rather than enhancing access to 
medicines in a global context.  
Panchal et al (2012) discussed the brand loyalty and the perception of the brand 
versus generic medicine in Indian pharmaceutical market. While health authorities 
and reimbursement systems in India prefer the lower priced generic products for the 
savings impact on health spending, the brand loyalty and perceived quality have 
major influence on use of brand medicines rather than generics in India.  
Companies currently spend one-third of all sales revenue on marketing their products 
- roughly twice what they spend on research and development (WHO, 2016). 
Communicating the brand pharmaceutical products by R&D company as superior to 
any generic medicines has been a social determinant in affecting the pattern of 
thought leaders use of brand pharmaceutical products.  The prescribing behavior also 
can be determinant in brand equity transferred from physicians to consumers. Panchal 
et al (2012) concluded that price was not studied as the only factor in determining 
brand versus generic consumption, the brand loyalty, awareness, and quality 
perception had major concern related to brand equity related to generics. 
 
The access to medicine index is an indicator that is based on the measurement of 
technical areas and performance indicators in low- and middle-income countries 
(LMIC) around the world. Its measurement covers variety of diseases, of these cases 
that it measures there are medicines for 14 non communicable diseases are measured 
for their access. The index is mainly focusing on the top 20 R&D pharmaceutical 
companies.  
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Figure 10: Accessto Medicines Index indicators and areas of measurement 
 
(Access to Medicine Index, 2016) 
We can obviously observe that one quarter of technical areas that influence access of 
pharmaceutical companies' medicines is the pricing. While on the horizontal plane 
there is the three quarters (75%) related to performance and transparency combined. 
So, for any company to launch its medicine, e.g.: NCD medicines, it has to make sure 
that pricing is transparent and the performance on the pricing mechanisms is solid and 
satisfying the real market economics. 
 
According to the Access to Medicines Index report in 2014, the affordability of 
medicines differs according to the payer whether patient or other reimbursement 
organization. The report assessed the pricing strategies considered by companies. It  
ensured that for multinational companies designing their launch of medicines, they 
consider socioeconomic factors for certain country in addition to the World Bank 
classification of country national income, i.e.: GDP. Moreover, the disease burden of 
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the country is another determinant for company strategy for need-based pricing 
according to a set of priority countries10 . 
 
As Egypt was one of the countries classified by the World Bank as LMIC, it was 
included in the report of the top 20 pharmaceutical companies. The report included 
companies that have brand medicines in addition to subset of generic medicines 
marketed in different countries. Access to medicines measured the company behavior 
in setting equitable pricing strategies and letting entry to the most affected markets 
with highest burden of the disease in scope. Equitable pricing strategies provided by 
the company is not the only indicator measured, but also the readiness for filing 
registration in the country to allow for access. 
 
One other indicator included in the index measure of the top 20 pharmaceutical 
companies is the patenting practices. The more flexible strategies the company has to 
allow for equitable access and competition among their existing brand and generics in 
the country, the higher their performance in the index. Companies can publicly agree 
to waive their patent rights and their data-exclusivity in certain regions with poor 
population in order to allow for more competition and hence increase access to more 
affordable medicines. Companies are measured for their fair use of flexibilities in the 
Doha Declaration and Trade-Related Aspects of Intellectual Property Rights (TRIPS) 
agreement if they are recorded as engaging in lobbying activities pushing the access 
to affordable medicines backwards. The indicators measured under this pillar are 
disclosure of licensing practice, and patent disclosure, and endorsement of trade 
policy (TRIPS) flexibilities. The company should have "voluntary licensing"11 
strategies and "non-assert declarations"12 for the patented products as well as 
technology transfer for medicines in scope.  
 
                                                             
10 Priority countries: are countries according tho the index that have the most five countries having 
the highest burden of the defined-disease and classified as low-income countries by the World Bank. 
11 A contract through which the patent-holder (the licensor) voluntarily permits a contracting party 
(the licensee) for the manufacture and distribution of a product. A non-exclusive voluntary license is 
when the license can be agreed with multiple licensees. 
 
12 A legally binding commitment that contains an explicit set of conditions، including permitted 
actions and designated territories, for which the patent owner commits not to enforce patent rights. 
This allows for a generic version of a patent protected product to be produced. 
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It is of great value to relate the access and availability of NCD medicines to 
the IP issues and measure required by governments. Wanis (2009) mentioned that IP 
issue is one determinant in access to medicines along other underlying economic 
conditions, illiteracy and prescription and consumption patterns. 
 
However, Mackey et al (2012) tested for any association between the NCD 
medicines on the Essential Medicines List (EML) and IP. Their results showed that 
none of WHO essential medicines has patent or data exclusivity. This important study 
exclude the patent issues from any concern of access to NCD and essential medicines. 
Any constraints of access to NCD essential medicines would be related to issues other 
than IP (Mackey, 2012). 
As we referred earlier in this review of literature that different quality of brand 
and its generics may be recorded, however as long as Mackey et al (2012) revealed 
that no medicine on EML has patent or data exclusivity and, hence, manufacturing 
data and techniques for those NCD medicine on EML brand medicines are available 
for its generics manufacturers and no longer protected. 
 
Non-Communicable Diseases (NCDs) affect adults in their productive years, require 
long term treatment and often cause disability. They can have more severe economic 
consequences for the individual and his or her family,—including decrease or loss of 
household income, impoverishment, loss of savings and assets, and reduced 
opportunities—than other illnesses. Amongst people suffering from chronic diseases 
in Egypt, for example, the probability of being employed is 25 % lower than the 
average, and their working time is reduced by 22 hours per week on average. NCD-
related health care costs can also significantly affect the financial security of the 
households. (Rocco et al, 2011) 
 
Acosta et al (2014) recommended that further research is required to evaluate the 
impact of the pricing policy on the medicines use and purchasing pattern. That is in 
our paper, we target the study of pattern of access to different medicine types in 
different socioeconomic areas. 
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Coming to the gap that this piece of research may cover in the literature above, 
this thesis adds to the literature by studying the association between the 
socioeconomic determinant represented by the rural and urban areas with contrast 
socioeconomic characteristics and the supply of medicine types; both brand and its 
generics. Supply side of brand versus generics with varying prices was not studied 
before for urban and rural areas. In some studies, only consumption pattern of 
generics was related to the patient characteristics of employment, literacy and 
education, age group.  
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Chapter 3: Methodology 
i. Data source 
 
In this research, we used secondary data published for the survey on medicines 
affordability and availability in Egypt conducted in 2013 (HAI, 2014). The data 
comprised 63 medicines treating Non-Communicable Diseases (NCDs).  
Data collected from a field survey from pharmacy outlets measuring the affordability 
of NCD medicines. Selected list of medicines covering major NCDs in Egypt were 
surveyed for the brand product and price of their available generic equivalent. 
Medicines for study in 2013 were chosen from the national Essential Medicines List 
(EML13.) in Egypt.  
 
Brand pharmaceutical product belongs to the innovator company that got the first 
license and developed the molecule of the medicine. Generic pharmaceutical products 
are those products having the same molecule of the innovator and are manufactured 
locally by Egyptian companies or imported from company other than the innovator.  
 
For the list of 63 medicines surveyed, prices of both brand and generic medicine type 
were recorded and calculated in different geographic areas covering seven 
governorates. Cairo, Giza, Qalyobia, Alexandria, Ismailia, Dakahleya, and Assiut 
were selected. Five pharmacy outlets were surveyed per area. A sum of 50 pharmacy 
outlets was surveyed and prices were recorded for the available brand medicine and 
one of its lowest available generic equivalent.  
 
ii. Study Design 
 
The study has a cross-sectional design. Three-step inclusion conditions were made. 
The available medicines in all outlets were recorded in a snapshot from every outlet 
when the data was collected.  
The three-step conditions were: 
                                                             
13 Essential Medicines List: is the list of medicines each country should have prime measures to secure 
access and market availability. The list pertain to country prevalence disease rate and priority health 
conditions. 
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1- Both brand and generic medicines are registered in MOH and marketed in Egypt. Any 
medicine with neither registered generics nor brand product in Egypt was excluded. If 
generic pharmaceutical products are marketed but the brand product is not registered, 
or if the pharmaceutical brand is registered and it has no generics registered, it is 
useless to include either in the study.  
In other words, choice between a brand and a generic medicine types should be valid. 
2- The medicine is on Essential Medicines List (EML).   
3- Either medicines; brand and generic, was recorded in at least all areas; rural and 
urban. If one medicine with its two types (brand and generic) was not observed in at 
least one survey area, it was excluded.  
The number of medicines we selected for our study is 39 medicines. Every 
medicine has one brand and product and one generic product; that is 78 product 
included in our study. These 78 medicines were recorded in 50 pharmacy outlets, that 
is our total observations are 3900 observations (n=3900). Every observation was 
made when a medicine type whether brand or generic is seen in a pharmacy outlet. 
Using this large number of observation is very healthy to the analysis of our paper. 
Data sets are used here to study the relationship between the supply of either generic 
or brand medicine to the different urban and rural areas from which data was 
collected.  
From a social equity perspective, we set the null hypothesis that brand and generic 
medicines have equal availability in rural and urban settings.  
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Table 7: List of medicines selected and their therapeutic classes (ATC 
classification) used in analysis 
Medicine Therapeutic Class   Medicine Therapeutic Class 
1 Acetyl salicyclic acid Antithrombotic Agents 21 Lactulose syrup Anti-constipation  
2 Allopurinol Anti-gout 22 Levodopa+Carbidopa Anti-Parkinson 
3 Amlodipine Cardiovascular 23 Levothyroxine Thyroid therapy 
4 Atenolol Cardiovascular 24 Lisinopril Cardiovascular 
5 Atorvastatin Anti-hyperlipidemic 25 Loratadine Antihistaminic 
6 
Betamethasone 
valerate Corticosteroids 26 Losartan Cardiovascular 
7 Captopril Cardiovascular 27 Meloxicam Anti-Rheumatic 
8 Carbamazepine Anti-epileptic agent 28 Meƞormin 500 Anti-diabetic 
9 Carvedilol Cardiovascular 29 Omeprazole Gastrointestinal  
10 Clopidogrel Cardiovascular 30 Paracetamol Analgesics 
11 Clozapine Psycholeptic 31 Phenytoin Antiepileptic 
12 Diclofenac Anti-Rheumatic 32 Propranolol Cardiovascular 
13 Digoxin Cardiovascular 33 Ranitidine Gastrointestinal  
14 Epoetin alpha injection 
Renal 
Failure/Antianaemic 34 Risperidone Psycholeptic 
15 Fluoxetine Psychoanaleptic 35 Salbutamol inhaler Chronic Respiratory 
16 Furosemide Cardiovascular 36 Simvastatin Anti-hyperlipidemic 
17 Glibenclamide Anti-diabetic 37 Sodium valproate syrup Antiepileptic 
18 Gliclazide Anti-diabetic 38 
Soluble regular human 
insulin Anti-diabetic 
19 Ibuprofen Anti-Rheumatic 39 Timolol eye drops Anti-Glaucoma 
20 
Isophane human 
insulin Anti-diabetic 
 
 
Relationship between the availability, recorded for both brand and generic medicine, 
and the type of socioeconomic class of geographic area; either urban or rural, will be 
analyzed by running Regression analysis.   
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iii. Organization of data 
 
The list of 39 medicines with 78 brand and generic types in 50 pharmacy outlets was 
modeled. We organized the data for every medicine recorded and coded per 
observation. Each medicine type (brand/generic) was recorded 50 times once in every 
outlet yielding 1950 observation for all brand medicines and 1950 for all generic 
medicines. We had 3900 observations (n=3900). 
  
As elaborated above that every medicine has one brand product and one generic 
equivalent. The observations were organized and responses were indicating the binary 
data for brand and generic medicine as 1 and 0, respectively.  
Price used is the market price divided by the pack size (tablets, capsules, milliliters of 
solutions or syrups, doses of inhalations, grams of topical preparations, etc…) to 
standardize the price measured per medicine in cases when brand and generic 
medicines of the same API have different pack sizes; e.g.: pack of 120 ml with pack 
of 125, or pack of 20 tablets with pack of 30 tablets. These data was shown under 
"unit price" column.  
Figure 11: Descriptive of price variable included in analysis using SPSS software 
 
iv. Processing of data 
 
In this model, dependent variable is brand/generic variable (br) coded as 1 for brand 
and 0 for generic. 
Minimum Mean Maximum
Prices .042 1.18340 7.321
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Independent variables are: unit price variable (pr) recorded as observed, urban/rural 
(ur) coded as 1 for urban and 0 for rural. The number of observations were 3900 
(n=3900). 
Extreme values of price that are more than 10-folds of the mean price were excluded 
(34 observations) leaving final observations of n=3866.  There were no missing cases. 
v. Limitations 
1- The study is a cross sectional data that shows only a snapshot of the availability of 
both brand and generic medicines selected for the survey. Further supply of the 
medicine in question may have been ordered prior to the survey and available at 
any other consecutive time. 
2- While the number of observations are quite good(n=3900), the number of 
medicines used in this analysis is relatively low (78 medicines against over 14,000 
medicine registered), and the number of outlets in the study (n=50) relative to the 
total number of pharmacies nation-wide is low (70,000) 
3- Prices used are for the unit price in local currency (EGP). Further devaluation of 
the currency occurred but was not considered in this study. 
4- The prices used were at that time of the survey in 2013. Some medicines may have 
increased/decreased in price due to some circumstances like shortages, or company 
appeals. 
5- The prevalence rate for the diseases treated by the medicines covered in this study 
is not available at the national level. This is one of the important recommendations 
to point out in the end of this research to establish an Egyptian registry for each of 
the NCDs, and other diseases. 
vi. Statistical Tools  
In this research, we used Logistic Regression Analysis to assess the association 
between the socioeconomic characteristic of the areas and the probability of a brand 
or generic medicine is available.  
In the Logistic regression, the dependent variable is a dummy variable (binary) either 
brand (1) or generic (0). The independent variables are also binomial rural as 
reference (0) and urban (1).  
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We used R programming software available online14. Codes for regression and 
diagnostics are included in this paper in the Annex. All factors described were not 
included in the final model. P-value and odds ratios were derived from this model. 
We also used the Statistical Package for Social Sciences software (SPSS). 
vii. Data Analysis: 
We used the Logistic Regression with following parameters considered: 
(br) : is dependent variable Brand 
(ur)  : is independent variable Urban 
(pr) : is independent variable Price 
(ur.pr) : is interaction variable between the two independent variables Urban*Price.  
 
The Logit model : 
݈݊ ൬ 
ܾݎ
1 − ܾݎ
൰ =  ߚ° + ߚ1ݑݎ +  ߚ2݌ݎ +  ߚ3ݑݎ. ݌ݎ + μ  
Where: 
ߚ°   is the constant of the equation 
ߚଵ  is the coefficient for the urban/rural variable 
ߚଶ  is the coefficient for the price variable 
ߚଷ  is the coefficient for the interaction of urban and price variables 
µ is the error term 
 
ܾݎ =  
1
1 + ݁ି(ఉ°ା ఉభ௨௥ା ఉమ௣௥ା ఉయ௨௥.௣௥)
 
It is easy to say that  
ߚ° +  ߚଵݑݎ +  ߚଶ݌ݎ +  ߚଷݑݎ. ݌ݎ →  +∞   when  ܾݎ → 1 
and when  
ߚ° +  ߚଵݑݎ +  ߚଶ݌ݎ +  ߚଷݑݎ. ݌ݎ →  −∞   when  ܾݎ → 0 
Then, br cannot be outside the range [0,1] 
The estimated marginal effect is given as follows: 
                                                             
14 Programming language and software environment used for statistical computing and graphics. The 
R language is widely used among statisticians and data miners for data analysis.  
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∆ ܾݎ
∆ ݑݎ
=  
ߚመ ݁ି(ఉ°ା ఉభ௨௥ା ఉమ௣௥ା ఉయ௨௥.௣௥)
(1 +  ݁ି(ఉ°ା ఉభ௨௥ା ఉమ௣௥ା ఉయ௨௥.௣௥))ଶ
 
=  ߚመ ܾݎ෢ (1 − ܾݎ෢ ) 
 
The logistic regression for the variables ur , pr , ur.pr gives the highest significance to 
the pr variable and highest Wald test value. Other variables significance were all 
above 0.05 significance level.  
Knowing that External Reference Price policy used sets the generic price lower than 
its brand by 30 and 35% as stated earlier in the pricing policy followed in Egypt, there 
is a very strong relationship between both variables; brand and price. This strong 
relationship with the highest significance minimized the significance of the other 
variable and the interaction, in other words covered for any existing relation between 
the brand and urban variables. 
To confirm what we had in the first estimate of regression, we estimated the 
regression again without the (ur) variable and found that significance of the price (pr) 
increased 10 times from 0.03 in the first model to 0.003 in the second one. That 
confirms the effect of significance of a highly significant variable in this equation to a 
relatively lower significant variable. 
The association between medicine type (brand, generic) and the price is already 
established by the current policy of pricing. 
To solve for that, we set price aside and estimate the model without the price variable 
to observe the significance of the other variable in absence of price. 
The new equation would be as follow: 
 
ܾݎ = ߚ° + ߚଵݑݎ +  ߚଶݑݎ. ݌ݎ  , 
Where: 
ߚ°   is the constant of the equation 
ߚଵ  is the coefficient for the urban/rural variable 
ߚଶ  is the coefficient for the interaction urban of and price variables 
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The regression in this scenario was better than with the variable pr giving very high 
significance lower than the 0.05 significance level and Chi square value for the model 
was 204.69 with degrees if freedom equals to 7 shown in the Annex. 
The model classification shows the success rate of 73.6 %. Where the percent of 
predicted cases to the actual observed cases are true (i.e.: that is the brand medicines 
were predicted and generic medicines were predicted with success rate of 73.6% 
shown in Figure 12: Predicted success for the regression model). 
 
Figure 12: Predicted success for the regression model 
 
 
 
The significance of the variables and their Wald values are shown below.  
Where the final equation can be put as follow:  
ܾݎ = 0.75 +  1.33ݑݎ +  1.38ݑݎ. ݌ݎ 
Sig. .000*** .009** .000*** 
Wald 47.77 6.915 131.634 
n      =      3866   
 
That is the null hypothesis is rejected and β1 is not equal to zero. That is the change in 
urban variable from rural (0) to urban (1) will increase the probability of brand 
medicines by 1.33 times than generic.  
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The ur.pr coefficient refers to that with reference to urban area fixed, when the price 
increases by one unit, the probability of the medicines to be a brand increases by 1.38 
folds.  
These interpretations confirms the alternative hypothesis that for urban areas there is a 
higher probability to have brand medicines available than generics, and in rural areas, 
the probability for brand medicines is lower. Given the area is fixed in urban, as the 
price of the medicine increases, the probability that it is a brand medicine is increased 
by 1.38 than in rural areas.  
So reject the null hypothesis of equal availability of brand product in rural and urban.  
Interpretation of results 
In this paper, we modeled the data for estimating the association between the 
probability of supply of brand or generic pharmaceutical product in urban and rural 
areas representing the different socioeconomic areas in Egypt.  
A total of 39 different medicines distributed in 16 therapeutic groups (ATC- level1) 
were identified.  
In our model, we organized the data and estimated the regression for the 3900 
observations in which all medicines (brand and generics) were recorded in all 50 
pharmacy outlets. Dependent variable which is the supply of brand/generic was 
dummy variable 1, and 0 for brand, generic type of medicines, respectively. 
Prices were used as independent continuous variable. Extreme values for the unit 
prices were excluded. The maximum price was 7.32, minimum was 0.042, and the 
mean was 1.18.  
The regression of supply of either brand or generic is strongly related with price rather 
than for urban and rural nature of the outlet. The association between medicine type 
(brand, and generic) and the price is well established and known. This association is 
not the focus of our study here. The significance of the other dummy variable 
(urban=1 and rural=0) and the interaction (urban.price) used were minimal. This 
minimal significance was attributed to the strong significance of the price variable 
included. So, regression was estimated again dropping the price variable. The model 
gave 73.6 % success rate of the predictions.  
The significance for the two variable; urban and urban.price variables were high at 
0.009, and 0.000; respectively. The coefficient logs produced were -0.288 for the 
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constant, 0.288 for the urban, and 0.326 for the urban.price, and odds ratio were 
obtained as 0.75, 1.334, 1.386; respectively. 
It is clear now from the final equation set for the model:  
ܾݎ = 0.75 +  1.33ݑݎ +  1.38ݑݎ. ݌ݎ 
that, given the socioeconomic characteristic of the area in which pharmacy outlet is 
located, the probability for brand medicine to be supplied is 1.3 times higher for urban 
rather than the area was rural. While in urban setting, and with the increase in price, 
the probability of the medicine supplied is brand increases by 1.38 times than rural 
areas. Rural areas are more likely to be supplied with generics rather than urban. The 
alternative hypothesis is now true. Brand medicines are more likely to be supplied and 
available in urban areas. Urban areas are with higher socioeconomic level than rural 
areas in Egypt. In this analysis, we did not include detailed characteristics of the urban 
and rural socioeconomic status as income, education level, and employment-
unemployment as data is not available and left for future studies. These detailed 
characteristics are related to consumers not to the supplier and their consumption 
patterns. The socioeconomic class of the area as a whole whether urban or rural is 
considered for the supply of either high priced brand or low priced generic. 
The results representation in our analysis is around 43% of Egypt population 
(CAPMAS, 2016), the seven governorates included had census of around 38.6 million 
people.  
 
Table 8: Governorates population inclueded in the study 
Governorate Population (census in million) Socioeconomic class 
Alexandria 4.805 Urban 
Assuit 4.241 Rural 
Cairo 9.265 Urban 
Dakahleya 5.942 Rural 
Giza 7.575 Mixed 
Ismailia  1.77 Urban 
Qalyoubia 5.098 Rural 
Total Governorate Populations 38.696 43% Percentage of 
total population 
Total Egypt 90.8  
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Chapter 4: Discussions and recommendations 
Insurance coverage 
While only 58% of Egyptians are covered by the public health insurance 
system, the financial burden of any illness is enormous as the percentage of the 
uninsured is higher in rural residents and those in the lowest socioeconomic levels 
(USAID, 2010). 
In Egypt, although there is a relatively well-established medical insurance system 
providing medical services through a large number of public facilities; it does not 
cover the whole population.  In order to be under the umbrella of the state medical 
insurance system, one has to be either a school student or a government employee. 
Accordingly, the high school dropout rate coupled with the high unemployment rate 
in the formal economy; mainly in the low-income level households have led to a high 
percentage of underprivileged patients who are uninsured.  These patients pay out of 
their pockets when in need for any medical intervention, let alone medicines and 
operations.  These out of pocket expenses represent a real burden.   
The access to health care services assessed in rural and urban areas in Egypt resulted 
in higher access to basic health care services in urban areas with higher 
socioeconomic pattern (Boutayeb, 2011). For example the access to assisted delivery 
for women in 2011 was around 81% and 48% for urban and rural Egypt; respectively. 
Figure 13:Rural-urban access to health services in Egypt. 
 
 (Boutayeb, 2011) 
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Expenditure on health 
Total health expenditures constitute 5.6% of GDP, and while private health 
expenditure is 60% of the total health expenditure, 97.6% of private health 
expenditure is for out of pocket (OOP) expenditure. Pharmaceutical expenses 
comprise 34.2 percent of total health expenditure and 42.6 percent of OOP spending 
on healthcare (WHO and WB, 2014). 
The public supply chain in MOH is vulnerable and is not properly structured 
leaving public health facilities with frequent stock-outs. As a result, patients often do 
not obtain their medication at the healthcare facility where it is prescribed, 90% of 
patients reported buying medication at a pharmacy, but only 10 % obtained 
medication at the facility itself (World Bank, 2010). Coupled with the absence of 
prescribing regulations, the dispensing of available medicines that are not actually 
needed by patients in public health care facilities is resulting in medicine misuse and 
misconsumption data. This has caused entry into the market of low-quality generics. 
 
Access to Medicines 
A socially equitable system provides the same level of quality health services to 
people with the same need, regardless of socioeconomic status, gender, place of 
residence, or any other potential difference, while an accountable system 
demonstrates and takes responsibility for performance to create high-quality health 
care (WB, 2015). Egypt scored 32.1 in 2004 on Gini15 Index and 30.1 in 1995 while in 
2008 its score was 30.8 (WB, 2016). Egypt has permanent inequality around the same 
range with no powerful intervention since 1995 introduced to alleviate this inequality. 
There are 17 pharmacists per 10,000 of the population. The number of private 
pharmacy outlets in Egypt is around 8 pharmacies per 10,000 of the population 
(MOH, 2015). By calculating the number of people entitled to benefit from the 
pharmacy outlet, every 1250 citizens are benefiting from every outlet assuming even 
distribution of outlets all of equal size businesses. In reality, this is not the case 
because there is heavy distribution of pharmacies in urban than rural. 
                                                             
15 Gini index measures the extent to which the distribution of income; consumption; expenditure 
among households within an economy that deviates from a perfectly equal distribution. Considered 
as a measure for social equity, Gini index of 0 represents perfect equality, while an index of 100 
implies perfect inequality. 
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Access is measured primarily by the availability of affordable medicines (WHO, 
2016). Affordability and prices survey was conducted in 2013 and found that mostly 
all medicines on the EML List for chronic diseases are affordable (HAI, 2014). As 
affordability was measured per medicine type (brand, and generic), availability here 
was measured per medicine type per geographic area having different socioeconomic 
characteristics.  
In urban and rural areas, poverty levels and hence expenditure on health is 
greatly different. In rural areas with lower socioeconomic level, however, the 
spending on health as percentage of annual individual expenditure is higher than 
urban areas. With the low economic and social pattern, illiteracy, and weak health 
awareness, disease burden is high in rural areas rather than urban. This can be 
illustrated while rural areas have more access and availability pattern of generic lower 
priced medicines, they, moreover, spend more OOP for their treatments. Chronic 
illnesses are life-long conditions that need permanent supply of medicines to improve 
health status and come in the good labor force for the society.  
The increased OOP expenditure on health is not only due to uninsured patients 
but also due to the medicines shortages in public healthcare system for those who are 
publicly insured. The public pharmaceutical supply chain is vulnerable and not well-
organized leaving weakness points of shortages and limited budgets and irregular 
supply to served areas.  
Globalization and access to medicines 
The impact of globalization on the pharmaceutical market is elaborated in 
cases of medicines with patents.  In Egypt, law number 82/2002 has several articles 
which ensures protection of public health preventing the abuse of the exclusive data 
protection allowing for voluntary licensing by the innovator and compulsory license 
by the government in cases of epidemics and public health crisis. Such actions are 
called TRIPS flexibilities which resulted from the Doha declaration 
To overcome this restriction and to protect the public health, several measures 
had been proposed by Doha Declaration; for example, compulsory licensing, 
voluntary licensing (breaking patency voluntarily and locally manufacture the 
medicine), importation from a country where patent is not valid, paying the patent 
company a reasonable fee to allow for generics, or parallel trade.  
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Parallel trade is where a patented medicine price in a country is lower than its 
price in another country. The medicine is transferred from the lower priced to higher 
priced country. Although this can be a solution to increase access to patented 
medicines, parallel trade can potentially benefit traders and mediators rather than 
patients themselves. This also creates parallel markets that can undermine the efforts 
for equitable international pricing system. The innovator company may be reluctant in 
the future to run the medicines in LMIC due to probabilities of parallel trade.  
 
Egyptian medicines regulatory intervention 
While local pharmaceutical market in Egypt has the characteristics of the 
market economy, the government intervention took different directions. CAPA, under 
the Ministry of Health, is the main regulatory body of the market and such 
interventions mostly initiated there.  
The first intervention in market is the "box" policy for registration. This 
policy created a restricted competition whereas monopoly at certain cases. The policy 
had mainly been proposed for introducing medicines to the market covering all 
therapeutic indications specifically those that are not of interest; e.g.: orphan drug, 
and low-profit margin products, medicines treating less prevalent and neglected 
diseases. While this policy is undesirable in Egypt limiting the competition, it was 
recommended to United Sates Food and Drug Administration (FDA) to restrict the 
entry of suppliers to remain in the interest of supplying medicines (Brown, 2016) 
To acquire its required impact, the "box" policy should be allowed for medicines with 
narrow therapeutic index with rigorous measures that ensure the equivalent quality 
and characteristics of both brand medicine and its generics. 
Quality of both brand and its generic medicine should be monitored closely not only 
by the bioequivalent tests but also by some other test to ensure the in-vivo availability 
and onset of action leading to the same desirable therapeutic effect. 
The second intervention is the obligatory/compulsory pricing; an 
intervention made by most government to ensure affordability to patients and prevent 
any monopolistic behavior on the one hand, and to limit health care expenditure on 
the other hand.  
External reference pricing used in combination with mark-up regulation kept prices as 
low as possible. Industry and pharmacists were satisfied with the existing prices for 
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definite time span till the devaluation of Egyptian pound took place. Pricing of 
medicine before devaluation differs than after, e.g.: a medicine priced in one reference 
country at $5 value will have local price of EGP 34 in 2013 while in 2016, it will be 
priced at EGP 39.5. Difference is around 14 % in the exchange rate, while global 
market prices are held stable. Noting that prices are approved for the life of Marketing 
Authorization (MA) period of 10 years and usually price revision will not occur upon 
re-registration process. 
On the flip side of the picture, the industry players including distributors and 
scientific offices study market well and define their registration, production, and 
importation plans based on their profitability rather than protecting public health.  
.  
Market Dynamics 
We will apply the understating to this issue in the inputs of the market economics 
related to the pharmaceutical market as follows in this section. 
Medicines are inelastic in demand; increase in prices will not impact the 
quantity purchased. Inelasticity of medicines for chronic conditions and life-saving 
situations is relatively higher than those used for acute conditions (WHO, 2015). As 
medicines used to protect health, the value of medicine is high to the patient paying to 
keep their health intact as much as they could and its high value differs from patient to 
patient according to the outcome it achieves. Medicines cannot be freely re-traded or 
resold by patients. 
The pharmaceutical market is not a perfect competitive market in which 
variety of reasons allow for market asymmetry. The asymmetry resulted from the lack 
of information on the demand side. Patients do not have the proper knowledge of their 
method of diagnosis or protocol of treatment as they refer to physicians to take 
decisions on behalf of them. Patients are left at the physicians' discretion, and 
sometimes at the pharmacist's directions during dispensing or consultation.  
From the supplier side, there is some bias to suppliers in which the 
pharmaceutical companies can influence the physicians' decision for treatments. 
Research and development that company had done in the clinical and preclinical 
phases are not always published and still exclusive for the patency time. Physicians 
are prescribing medicines based on the available knowledge, so companies can 
influence the physicians' tendency to prescribe one medicine or another. 
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In Egypt, there are no clear prescribing guidelines. There is no clear guidance 
or regulations regarding the promotion of prescription medicines for pharmaceutical 
suppliers. The role of the pharmacist as drug expert is not practiced on the ground. 
The legislative structure has to be reformed. The only limitation to bias in information 
knowledge is the regulation restricting the sale of medicines only by pharmacists. 
While the demand side is as much important as the supply side, the irrational use of 
medicines adds to the cost of health care interventions by the medicines misused 
qualitatively and quantitatively. Lack of rational use of medicines prevents the right 
decisions regarding both demand side in determining proper procurement decisions 
and the supply side from proper supply and manufacture decisions made in the 
pharmaceutical market. 
 
If we consider public health is public goods, the government should have the 
capabilities to regulate and protect the public health. This occurs by the regulating 
pharmaceuticals and establishing control on the market preventing the falsified 
medicines or counterfeit to be on the market. Controlling market can take other forms 
of putting some barriers to entry of any medicine that can harm the public health 
instead of saving it. So the regulations of pharmaceuticals and pricing policy are part 
of government intervention to protect the public health as public goods. Subsidies 
should be provided to pharmaceutical suppliers to ensure the appropriate supply to the 
market to sustain the protection of public health, and prevent any shortage in 
medicines. 
Pricing can also be controlled by market power of the demand side. Some 
times to influence markets, suppliers my lobby to form oligopoly that change the 
market price of certain medicine category alternatives. The intervention of the 
government in this case would be best if monopsony is practiced. Monopsony is the 
case when there is only one consumer on the demand side, while there are multiple 
suppliers in the market. Every supplier will offer the best price for the medicine and 
the competition is for the sake of the patient. One form of the monopsony is the 
public/social health insurance scheme that covers all population. 
Monopsony also can be exerted in cases of patented medicines when there is 
monopolistic power from the supplier. The demand power by single player on the 
demand side will decrease the supplier power allowing for negotiating price. This can 
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also take place when one or two medicines are registered for one API. If the API is 
used to treat certain chronic condition and the medicines are imported, then the 
monopolistic power of the supplier can be expected. In this case prevalence16 rates 
and disease pattern are extremely important to the monopsony of the government and 
to induce generic competition because leaving the medicines supply used for the 
chronic condition or NCD under the supplier's power is failure to protect the public 
health. Pooling of demand of medicines, not only within the health care system, but 
also in the wider society, is needed to increase purchasing power and insure 
accessibility. 
 
One of the pricing policies adapts the maximum price, which is a price ceiling 
and the medicine in the market should not exceed that price. Price ceiling will not be 
effective if it is above the equilibrium price, however it may generate shortages if it is 
far below the equilibrium. We can recommend here that price ceiling can be followed 
provided that the equilibrium price should be known to the regulator.  
Price controls will be optimum if price ceilings made are satisfying the market 
equilibrium or very closely around it (equilibrium here means demand of medicines; 
i.e.: prevalence of diseases and standard treatment guidelines, are met with proper 
supply type and quantity).  
For the medicines demand to be accurate and powerful, the single buyer concept 
(social health insurance covering majority of population) shall potentiate the power of 
the regulator to set prices. Prices to be fair meeting the supplier's expectations and 
planning, the exact demand for medicines should be based on the consumption pattern 
for every medicine and to be related to the prevalence rate of diseases.  
The consumption pattern for medicines can be easily obtained by a new 
intervention some governments began to use recently called "Pharmaceutical Track 
and Trace" system and policy. In the policy, every medicine registered in the country 
is traced per pack. Every pack of the medicine is recorded on the central database 
once it is manufactured and labeled a unique code for identification. Any transaction 
on this specific pack will be recorded by the database allowing for exact map of 
distribution and patterns of consumption and locking the market against any parallel 
                                                             
16 The prevalence rate of diseases is the proportion of population who has a particular disease over a 
specified period of time. This proportion includes not only new cases, but also old cases remained ill 
during the specified period in time. 
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illegal trade of falsified counterfeit medicines provided that all stakeholders are 
involved in the process. Upon analyzing the data we have for every medicine, then 
national demand is well known and the government can leverage to set the ceiling 
price at the equilibrium price. In this scene, both sides of suppliers and buyers are 
recorded and any surplus would be apparent. 
Coupled with the fair health insurance scheme, the "Pharmaceutical Track and 
Trace" can effectively integrate with the reimbursement organizations and monopsony 
will be exerted in a perfect scenario. Brand and generic pharmaceutical products will 
be the same in determining the fair market equilibrium price and lower/higher 
socioeconomic class do not have to worry about their healthcare cost or access to 
either type of their medicine (brand, and generic). Pricing policy in this case may 
follow either "Price Ceiling" or "Volume Agreement" policy. The first can be applied 
when insurance coverage is not covering the whole population and still there are 
proportions of population have to pay OOP expenses to buy their medicines.  
The second policy, "Volume Agreement", is best fit when there is single buyer with 
exact demand quantity when the negotiating power will be high.  Using pharmaco-
economic evaluations to help with setting the fair market equilibrium price is 
recommended. Under "Volume Agreement", the agreed drug price is based on a 
forecast volume of sales. If the actual volume exceeds the forecast, the drug price 
usually has to be lowered. The health insurance coverage has a prominent advantage 
of lowering pricing by the power of purchasing and reimbursement through the 
government, or health insurance body. This recommendation is feasible upon 
coverage of majority of the population by health insurance scheme.  
Governments' interventions should maximize the buying power by pooling of 
purchases. The government should be armed with some essential tools, for example 
resources for pharmaco-economic analysis, informed decisions about the buying and 
selling parties in the market, the segmentation using International Drug Price 
Indicator Guide (MSH, 2016). The utmost goal to protect the public health will be 
done in a perfect behavior. 
Most of the evidence from LMIC suggests that health insurance is associated 
with 1- increased use of medicines, 2- a reduction in the financial barriers to access, 
3- more rational use, 4- and improved health outcomes (Faden et al, 2011). 
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The social health insurance should use internal generic reference pricing to set 
reimbursement rates. This recommendation has combined effects. Although this can 
successfully reduce medicine prices and encourage patients to choose more cost-
effective medicines, generic reference pricing may not reduce overall medicine 
expenditures since it does not guarantee efficient medicines prices or impact the 
quantity of medicines prescribed (Faden et al, 2011). 
Focusing on individual strategy for medicines improvement will produce non 
preferable outcome. Combined strategies have to be pluralized and put in place to 
integrate one another. For example, in Kyrgyzstan a combination of generic reference 
pricing, consumer education about payment responsibilities, and price negotiation 
with suppliers established stable market pricing for medicines and improved patient 
access (Faden et al, 2011). 
Egypt should use leverage to improve supplier and consumer practices, and to 
potentially lower industry prices, insurance systems with substantial membership can 
have overall effects on the health sector itself as externalities to combined medicines 
strategy. Consolidated system of public purchasing of medicines should be in place 
allowing for lower transaction costs and increased leverage for negotiating prices with 
the suppliers. 
While the burden of NCDs is rising, it can constitute a major health challenge 
of access to affordable NCDs medicines. The government can use differential co-
payment level for insuring consumers. This will act as an incentive for patients to 
choose the medicine of interest according to their preferences not according to the 
supplier. Moreover, neglected and orphan diseases common in the lower 
socioeconomic class should be resolved properly through Social Health Insurance. 
 
The results of innovative research into needed medicines should be regarded as a 
global public good. Under the present system of incentives based on exclusive 
property rights, public and private investment in R&D is recovered through a 
temporary monopoly that results in high non-competitive prices. Unless alternative 
mechanisms are established that isolate incentives for innovation from prices, 
regulators should be aware that pricing can be regarded as a reward for past 
innovation and incentives for future R&D. 
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The argument of choice between brand and generic is assuming that quality is 
guaranteed. National regulatory authorities for medicines in countries have the prime 
responsibility to ensure that medicines in use are safe and of assured quality, 
preventing the presence of falsified or substandard medicines in the market. 
Poor-quality medicines are known to cause harm to patients, not only suboptimal 
treatment outcomes but also serious disability or death in some cases. Regulatory 
authorities for medicines in low- and middle-income countries often have inadequate 
capacity to properly monitor the quality of medical products along their entire life 
cycle, including oversight of pharmaceutical company activities to ensure compliance 
with good manufacturing practices and other standards that ensure that both locally 
manufactured and imported medicines are of adequate quality and efficacy (WHO, 
2015). Quality should be regularly monitored and ensured against global standards for 
both medicines; brand and its generic. Good governance for medicines framework to 
enhance the regulatory performance should be followed.  
Solutions for the social equality with respect to availability of both brand and 
generic medicines in the urban and rural areas are required. On the one hand, social 
health insurance, illiteracy eradication, and increasing awareness of healthcare in rural 
areas may help increase availability of brand medicines in lower socioeconomic areas. 
On the other hand, improving availability of generics in urban areas may require 
assured equal quality of generic medicines, setting regulations for prescription 
medicines guidelines and prescribing medicines in non-proprietary names. The utmost 
goal to protect the public health will be done in a perfect behavior.  
The good governance in medicines should allow for transparent practices in 
pricing. Conflicts of interest should be declared for all market stakeholders and 
regulators. The non-profit organizations and other society members should have role 
in the negotiating power of prices.   
The good governance for medicine framework should be monitored and evaluated 
periodically with the assistance of WHO. Transparency measures should be in place. 
 
 The following Figure 14: Visual presentation of policy intervention and 
author's recommendations shows how the implementation of some recommendations 
can explicitly improve the overall performance of the healthcare system and 
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governance. Social health insurance coupled with "Track and Trace for 
Pharmaceuticals", patients can be dispensed their medicines of choice when 
prescribed by the physician. When the physician follows the prescribing guidelines, 
and when industry adheres to the medicines promotion regulation, patient choice of 
either medicine can be well practiced. Both generic and brand medicines will be 
available for the patient in either urban or rural areas. The "Pharmaceutical Track and 
Trace"; where all market transactions for all medicine packs, will be used to verify the 
reimbursement system, and to generate real-time data for supply and demand in the 
market allowing for equitable and fair pricing policies. Such policies and practices 
will lead to the equilibrium of the pharmaceutical market in Egypt.
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Figure 14: Visual presentation of policy intervention and author's recommendations 
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Conclusion 
 
Medicines are important treatment interventions to promote health for people. 
Every medicine has a brand and generic product. Equal access to both types of 
medicines is part of equal access to health care in different socioeconomic areas.  In 
this research, we used secondary data published for the survey on medicines 
affordability and availability in Egypt conducted in 2013 (HAI, 2014). We applied 
some inclusion criteria and 39 medicines were selected treating Non-Communicable 
Diseases (NCDs).  
Our hypothesis stands for the assumption of social equity that presumes equal access 
to medicine alternatives for varying rural/urban population especially in chronic 
conditions that last long and necessitate treatments for life.  
We modeled the data and used logistic regression. Results were produced using 
statistical software. 
Primary findings show that rural and urban areas have different pattern of market 
supply; hence availability of both brand and generic medicine types. The urban areas 
are 1.3 times higher than rural to be supplied with brand type medicines. In the same 
settings of socioeconomic area, the probability of supply of brand rather than generic 
medicines increases by the increase in price. 
Social health insurance coupled by pharmaceutical Track and Trace system and 
combined pricing mechanisms should be in place to insure equilibrium between 
market supply and demand and equal access to medicines. Guidelines for promotion 
of prescription medicines, guidelines for prescribing practices should be in place to 
improve the market equilibrium.  
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Annex I: Statistical results in SPSS 
 
Descriptive of the data variables used in logistic regression: 
 
Available 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Not Available 895 23.2 23.2 23.2 
Available 2971 76.8 76.8 100.0 
Total 3866 100.0 100.0   
      Urban/Rural variable 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Rural 1933 50.0 50.0 50.0 
Urban 1933 50.0 50.0 100.0 
Total 3866 100.0 100.0   
      Brand/Generic variable 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Generic 1933 50.0 50.0 50.0 
Brand 1933 50.0 59.0 100.0 
Total 3866 100.0 100.0   
 
Price variable 
  Minimum Maximum Mean Std. Deviation 
pr .042 7.321 1.18340 1.503883 
Valid N (listwise)         
 
 
 
 
The best fitting Model 
 
 
 
 
 
 
 
 
 
Goodness of Fit 
Step Chi-square Df Sig. 
1 204.691 7 .000 
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Classification Tablea 
Observed 
Predicted 
br 
Percentage 
Correct generic brand 
Step 1 br generic 1574 356 0.41 
brand 849 1087 0.28 
Overall Percentage     0.73 
a. The cut value is .500 
 
Parameter Estimates 
  Estimate Std. Error Wald df Sig. OR 
  Constant -2.880E-01 .101 .000 1 .000 .750 
Location ur .288 .110 6.915 1 .009 1.334 
interaction .326 .028 131.634 1 .000 1.386 
 
Other Models 
 
1- The Regression of Brand (br) with both variable urban (ur), and price (pr) and 
interaction variable (ur.pr): 
Parameter Estimates 
  β S.E. Wald df Sig. OR 
  Constant .130 .118 1.210 1 .271 1.138 
Location ur -.158 .125 1.605 1 .205 .854 
pr .216 .103 4.376 1 .036 1.241 
interaction .110 .107 1.060 1 .303 1.117 
 
2- The Regression of Brand (br) with variable price (pr) and interaction variable 
(ur.pr): 
Parameter Estimates 
  Estimate Std. Error Wald df Sig. OR 
  Constant .271 .039 47.437 1 .000 1.311 
Location interaction .040 .095 .180 1 .671 1.041 
pr .279 .094 8.836 1 .003 1.322 
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Annex II : Statistical Calculations in R 
 
The statistics calculations done in R software were following the model iterations as 
follow: 
The code used for programming of the data file as to do the following: 
1- Read data file 
2- Summary of data file 
3- Programming of logistic regression parameters and variables 
4- Testing for significance and other parameters evaluations. 
 
# read data file, name it "m" 
m<- read.csv("m.csv", TRUE) 
# give summary about the data 
summary(m) 
#show part of data file 
print(head(m)) 
#creating logistic regression "g" for data with dependent 
variable is br and independent variable ur with interaction of 
ur.pr excluding the pr variable 
g<- glm(br~ur+(ur*pr)-pr, data=m, family="binomial") 
# give summary of the regression parameters 
summary(g) 
# give the odds ratio for parameters 
exp(coef(g)) 
 
The results are shown in R as follow: 
  av br ur     pr 
1  1  1  1 7.3214 
2  1  1  1 7.3214 
3  1  1  1 7.3214 
4  1  1  1 7.3214 
5  1  1  1 7.3214 
6  1  1  1 7.3214 
 
Call: 
glm(formula = br ~ ur + (ur * pr) - pr, family = "binomial",  
data = m) 
 
Coefficients: 
                     Estimate                Pr(>|z|)     
(Intercept)         -2.88e-1                 0.000 *** 
ur                  -0.28813                 0.009  **  
ur:pr                0.32608                <2e-16 *** 
--- 
Signif. codes:  0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05 ‘.’ 0.1 ‘ ’ 1 
 
Number of Fisher Scoring iterations: 4 
Odds ratio 
(Intercept)            ur               ur:pr  
  0.750769          1.334243          1.386868  
 
Showing results for the regression with the independent variable urban (ur), price (pr), 
and interaction variable urban*price (ur.pr): 
#creating logistic regression "g1" for data with dependent 
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variable br and independent variables ur, pr with interaction 
of ur.pr variable 
g1<- glm(br~ur*pr, data=m, family="binomial") 
# give summary of the regression parameters 
summary(g1) 
 
The following results were produced: 
Call: 
glm(formula = br ~ur * pr, family = "binomial",  data = m) 
 
Coefficients: 
                     Estimate              Pr(>|z|)     
(Intercept)         0.130460                0.271  
ur                 -0.158262                0.205    
pr                  0.216864                0.036 * 
ur:pr               0.110354                0.303  
--- 
Signif. codes:  0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05 ‘.’ 0.1 ‘ ’ 1 
 
Showing results for the regression with the independent variable price (pr), and 
interaction urban*price (ur.pr) variable: 
#creating logistic regression "g2" for data with dependent 
variable br and independent variables pr with interaction of 
ur.pr variable excluding the ur variable 
g2<- glm(br~pr+(ur*pr)-ur, data=m, family="binomial") 
# give summary of the regression parameters 
summary(g2) 
 
The following results were produced: 
Call: 
glm(formula = br~pr+(ur*pr)-ur, family = "binomial",  data = 
m) 
 
Coefficients: 
                     Estimate               Pr(>|z|)     
(Intercept)         0.271460                0.000 ***  
pr                  0.279864                0.003 ** 
ur:pr               0.040354                0.671  
--- 
Signif. codes:  0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05 ‘.’ 0.1 ‘ ’ 1 
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Annex III: Egypt affordability survey findings 
 
Some of the findings shown in the affordability survey for NCDs medicines 
conducted in Egypt in 2013 (HAI, 2014). The days of wage spent for medicines are 
based on minimum wage projected in 2014 to EGP1200 (EGP40/ day) .   
Medicine and number of units required for 30-days treatment 
Number of days of wage required 
to purchase the treatment for 30 
days (B=Brand medicine, 
G=Generic Medicine) 
Diabetes 
Glibenclamide 5mg x60 0.5 B/ 0.2 G 
Meƞormin 500mg x90 0.7 B / 0.5 G 
Gliclazide 80mg x30 0.3 B / 0.2 G 
Isophane insulin 100IU 10ml  0.8 B / 0.8 G 
Regular insulin 100IU 10ml 0.8 B / 0.8 G 
Cardiovascular disease 
Amlodipine 5mgx30 1.7 B / 0.6 G 
Atenolol 50mgx30 0.4 B / 0.1 G 
Captopril 25mgx60 0.8 B / 0.5 G 
Carvedilol 25mg x30 2.1 B / 0.9 G 
Digoxin 0.25mg x30 0.1 B / 0.1 G 
Lisinopril 10mg x30 1.1 B / 0.6 G 
Losartan 50mgx30 2.8 B / 1.4 G 
AtorvastaƟn 10mg x30 3.2 B /1.7 G 
SimvastaƟn 20mg x30 4.3 B / 2.1 G 
Acetyl salicyclic acid 100mg x30 0.4 B / 0.1 G 
Clopidogrel 75mg x30 5.5 B / 1.5 G 
Respiratory disease 
Salbutamol 100mcg/dose x1 inhaler (200 doses) 0.3 B /0.3 G 
Mental health /neuroleptic disorders 
FluoxeƟne 20mg x30 3.5 B / 0.7 G 
Carbamazepine 200mg x90 1.2 B / 1.0 G 
Clozapine 25mg x90 1.8 B / 1.2 G 
Risperidone 2mgx90 14.0 B / 5.0 G 
Other NCDs 
Diclofenac 25mg x60 0.6 B / 0.3 G 
Ibuprofen 400mg x90 4.1 B / 3.2 G 
Levodopa+carbidopa 250/25mg x90 4.5 B /2.7 G 
Omeprazole 20mg x30 2.9 B / 0.7 G 
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Annex IV: The pricing sources in different countries 
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